Clinical Trial Protocol
TITLE PAGE
Document Number: c03484701-03
EudraCT No.: 2015-002619-14
BI Trial No.: 1199.36
BI Investigational 
Product :Nintedanib ( Ofev®)
Title:INSTAGETM: A 24 -week, double -blind, randomized, parallel -
group stud y evaluating the efficacy and safet y of oral 
nintedanib co-administered with oral sildenafil, compared to 
treatment with nintedanib alone, in patients with idiopathic 
pulmonary  fibrosis (IPF) and adva nced lung function 
impairment
Brief Title:Efficacy  and safet y of nintedanib co -administered with 
sildenafil in I PF patients with advanced lung function 
impairment
Clinical Phase: IIIb
Trial Clinical 
Monitor:
Phone : Fax: 
Coordinating 
Investigator:
Phone ext  (Division), (Clinic) 
Fax
Status: Revised Protocol based on Global Amendment 2
Version and Date: Version: Date:
3.0 18AUG 2016
Page 1 of 100
Proprietary confidential information .
2016 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not -in full or in part -be passed on, reproduced, published or otherwise used without prior written permission.

Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 2of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
CLINICAL TRIAL PROTO COL SYNOPSIS
Nam e of company: Boehringer Ingelheim 
Nam e of finished product:Ofev®
Nam e of active ingredient: Nintedanib
Protocol date:
30Dec 2015Trial number:
1199.36Revision date:
18Aug 2016
Title of trial:INSTAGETM: A 24 -week, double -blind, randomized, parallel -group 
study  evaluating the efficacy  and safet y of oral nintedanib co-
administered with oral sildenafil, compared to treatment with 
nintedanib alone, in patients with idiopathic pulmonary  fibrosis (IPF) 
and advanced lung function impairment
Coordinating
Investigator:
Phone ext (Division), (Clinic) 
Fax 
Trial sites :Multi -centre trial
Clinical phase:III b
Objective(s):To assess efficacy  and safety  of concomitant treatment with 
nintedanib and sildenafil in I PF patients with advanced lung 
function impairment . 
Methodology: Double- blind, randomized, parallel design comparison of 
nintedanib 150 mg bid and sildenafil 20 mg tid to nintedanib 150 
mg bid and placebo matching sildenafil tid over 24 weeks
No. of patients: 
total entered:
250 patients
each treatm ent:
Randomization 1:1
125 patients assigned to each treatment arm.
Diagnosis :Idiopathic Pulmonary  Fibrosis (I PF)
Main criteria
for inclusion:Written informed consent;

Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 3of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Nam e of company: Boehringer Ingelheim 
Nam e of finished product:Ofev®
Nam e of active ingredient: Nintedanib
Protocol date:
30Dec 2015Trial number:
1199.36Revision date:
18Aug 2016
Male or female patients aged ≥ 40 y ears at visit 1;
IPF diagnosis based upon the ATS/ERS/JRS/ALAT 2011 guideline 
for < 6years; confirmation of diagnosis by investigator based on   
chest HRCT perfor med within 1 8months of visit 1 and surgical 
lung biops y (if available);
DLCO(corrected for Hb) ≤ 35% predicted of normal at visit 1
Test product(s):
Nintedanib and sildenafil
dose:Nintedanib: 300 mg daily  (150 mg bid) with possibility  to reduce 
to 200 mg dail y (100 mg bid) to manage adverse events
Sildenafil : 60 mg daily  (20 mg tid)
mode of 
admin istration : p.o.
Comparator products:
Nintedanib and placebo matching sildenafil
dose:Nintedanib: 300 mg daily  (150 mg bid) with possibility  to reduce 
to 200 mg dail y (100 mg bid) to manage adverse events
Placebo matching s ildenafil: Not applicable
mode of 
admin istration : p.o.
Duration of treatm ent:
24 weeks of randomized treatment
EndpointsPrimary  Endpoint: Change from baseline in SGRQ total score at 
week 12
Secondary  Endpoint s:
Change from baseline in dy spnea using UCSD SOBQ at
week 12;
Change from baseline in SGRQ total score at week 24;
Change from baseline in dy spnea using UCSD SOBQ at
week 24 ;
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 4of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Nam e of company: Boehringer Ingelheim 
Nam e of finished product:Ofev®
Nam e of active ingredient: Nintedanib
Protocol date:
30Dec 2015Trial number:
1199.36Revision date:
18Aug 2016
Percentage of patients with on- treatment SAEs from baseline 
to week 24.
Safety criteria :Adverse events (especially  SAE and other significant AE) , phy sical 
examination including weight, 12 lead electrocardiogram and vital 
signs, laboratory  evaluations.
Statistical m ethods:
Mixed Effects Model for Repeated Measures (MMRM) for 
continuous endpoints and Kaplan -Meier and Cox model for time to 
event endpoints, Cochran -Mantel -Haenszel test for binary  endpoints
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 5of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
FLOW CHART
Trial PeriodsScreening 
PeriodRandomized Treatm ent PeriodFollow
-up 
period
Visit 112143 4 56 715Dose 
Adjustment 
visit16Early
EOT17FUP18
Weeks 0 4 8 12 18 24 +4
Days -28 to -1 1 29 57 85 127 169 +28
Time window  for visits none±3
days±3
days±3
days±7
days±7
days+7
days
Informed consent2X
Dem ographics X
Medical history X
SGRQ, UCSD -SOBQ, EQ -
5D3 X X X X X
Physical examination4X X X X X X X X X X
Vital signs X X X X X X X X X X
Laboratory tests X X X X X X X X X
 
 
 
 
 
Pregnancy test (urine)7X X X X X X X X X
12 lead -ECG X X X X X
Spirometry X X X X X X X X
DLCO , VA8X X X X
Resting SpO 2 X X X X X
Resting PaO 2and PaCO 29X X X X
Echocardiogram X
Revie w of in-/exclusion 
criteriaX X
Randomization X
Access IRT X X X X X X X X
Dispense trial drugs X X X X X
Collect trial drugs & 
compliance checkX X X X10X X X
Dispense or review  patient 
diary11 X X X X X X X X
Adverse events X12X X X X X X X X X
Acute exacerbations X X X X X X X X X X
Concomitant therapy X X X X X X X X X X
Completion of patient 
participationX
Vital status collection13X

Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 6of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
1. The period between visit 1 and 2 should last a maximum of 28 days. Eligible patients can be randomized once central 
lab results have been received and are found to be consistent with eligibility criteria. 
2. At site discretion, informed consent may be obtained on one day and the remainder of the screening procedures can 
follow . 
3. SGRQ , UCSD -SOBQ and EQ -5Dare to be completed in this order and prior to any other trial related procedures. 
4. Physical examination to include weight measurement at all visits. At visit 1, height measurement should be included. 
 
 
 
 
 
 
7. Urine dipstick pregnancy tests will be provided by central lab and should be performed in all women of childbearing 
potential. If urine test is not acceptable to local authorities, a blood test can be done at a local laboratory.
8. The DLCO/VA assessment should alw ays be performed after the FVC assessment.
9. Arterialised blood gases (PaO 2and PaCO 2) will be measured at selected sites experienced in
earlobe blood gas 
sampling.
10. At visit 6 drug supplies should be collected for accountability and compliance check and re -dispensed to the patient.
11. Patient diary will be issued at visit 2 until visit 7. Diary to be reviewed with patient at every visit. Content to be 
discussed as it pertains to AEs, concomitant therapy , medication compliance and drug administration preceding PK
sampling . 
12. Adverse events should only be collected at this visit if occurring after obtaining the informed consent. Medical 
conditions present at time of the informed consent should be recorded in the medical history.
13. Patients who complete an early End of Treatment visit and don’t accept to attend all remaining planned visits will be 
contacted for vital status collection at week 24. This can be done by phone.
14. Visit 2 is defined as baseline assessment if the respective parameter is planned to be collected a t that visit. Otherwise, 
visit 1 will serve as baseline assessment.
15. Visit 7 is the End of Treatment (EOT) visit for patients who complete the treatment period as planned.
16. In case of dose change of nintedanib (reduction or re -escalation), dose adjustment vi sit must be conducted to allow 
dispensing of new medication kit.  
17. Early e nd of treatment visit to be completed for all patients who withdraw or discontin ue all study drugs prematurely .
These p atients will be invited to attend all remaining visits as plann ed until week 24 (Visit 7). The following procedures 
are no longer required in the visits to be conducted after theearly EOT visit: laboratory tests, biomarker sampling, 
pharmacokinetic sampling and ECG.
18. A follow up visit needs to be completed 28 days (+7 days) after the last drug administration for all patients. Patients 
who prematurely discontinue all study drugs but accept to conduct all remaining study visits as planned and the 
remaining duration in the trial is longer than 28 days after the last drug administration are exempted from this visit .

Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 7of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
TABLE OF CONTENTS
TITLE PAGE ........................................................................................................................... 1
CLINICAL TRIAL PROTO COL SYNOPSIS ..................................................................... 2
FLOW CHART ........................................................................................................................ 5
TABLE OF CONTENTS ........................................................................................................ 7
ABBREVIATIONS ................................................................................................................ 11
1. INTRODUCTION ............................................................................................... 13
MEDICAL BACKGROUND ............................................................................. 13 1.1
DRUG PROFILE ................................................................................................ 14 1.2
1.2.1 Nintedanib ................................
............................................................................ 14
1.2.2 Sildenafil .............................................................................................................. 16
2. RATIONALE, OBJECTIVE S, AND BENEFIT -RISK ASSESSMENT .....18
RATIONALE FOR PERFOR MING THE TRIAL ......................................... 18 2.1
TRIAL OBJECTIVES ........................................................................................ 19 2.2
BENEFIT - RISK ASSESSMENT ..................................................................... 19 2.3
3. DESCRIPTION OF DESIG N AND TRIAL POPULATI ON......................... 21
OVERALL TRIAL DESIGN AND PLAN ....................................................... 21 3.1
3.1.1 Administrative structure of the trial ................................
................................. 21
DISCUSSION OF TRIAL DESIGN, INCLUDING TH E CHOIC E OF 3.2
CONTROL GROUP(S) ...................................................................................... 23
SELECTION OF TRIAL P OPULATION ....................................................... 23 3.3
3.3.1 Main diagnosis for trial entry ............................................................................ 23
3.3.2 Inclusion criteria ................................................................................................. 24
3.3.3 Exclusion criteria ................................................................................................ 24
3.3.4 Removal of patients from therapy or assessments........................................... 27
Removal of individual patients ............................................................................. 27 3.3.4.1
Discontinuation of the trial by  the sponsor ........................................................... 28 3.3.4.2
4. TREATMENTS ................................................................................................... 29
TREATMENTS TO BE ADM INISTERED ..................................................... 29 4.1
4.1.1
Identity of BI investigational product and comparator product.................... 29
4.1.2 Method of assigning patients to treatment groups........................................... 29
4.1.3 Selection of doses in the trial .............................................................................. 30
4.1.4 Drug assignment and administration of doses for each patient ...................... 30
Nintedanib ............................................................................................................. 30 4.1.4.1
Sildenafil and matching placebo ........................................................................... 31 4.1.4.2
4.1.5 Blinding and procedures for unblinding ........................................................... 31
Blinding................................................................................................................. 31 4.1.5.1
Unblinding and breaking the code ........................................................................ 32 4.1.5.2
4.1.6
Packaging, labelling, and re- supply ................................................................... 32
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 8of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
4.1.7 Storage conditions ............................................................................................... 33
4.1.8 Drug accountability ............................................................................................. 33
CONCOMITANT THERAPY, RESTRICTIONS, AND RE SCUE  4.2
TREATMENT ..................................................................................................... 33
4.2.1 Rescue medication, emergency procedures, and additional treatment.......... 33
Recommendations for managing AEs (exceptions include diarrhoea and liver 4.2.1.1
enzy me elevations) ................................................................................................ 34
Recommendations for managing diarrhoea .......................................................... 34 4.2.1.2
Recommendations for managing liver enz yme elevations ................................... 36 4.2.1.3
4.2.2 Restrictions .......................................................................................................... 37
Restrictions regarding concomitant treatment ...................................................... 37 4.2.2.1
Restrictions on diet and life sty le.......................................................................... 39 4.2.2.2
Restrictions regarding women of childbearing potential ...................................... 39 4.2.2.3
TREATMENT COMPLIANCE ........................................................................ 39 4.3
5. VARIABLES AND THEIR ASSESSMENT .................................................... 40
TRIAL ENDPOINTS .......................................................................................... 40 5.1
5.1.1 Primary Endpoint ................................
............................................................... 40
5.1.2 Secondary Endpoints .......................................................................................... 40
.............................
............................................................... 40
ASSESSMENT OF EFFICA CY........................................................................ 41 5.2
5.2.1 Patient Reported Outcomes
............................................................................... 41
5.2.2 Forced Vital Capacity, Carbon Monoxide Diffusion Capacity , Alveolar 
Volume, Oxygen Saturation and Arterialised Blood Gases ............................ 41
5.2.3 Acute IPF exacerbations ..................................................................................... 42
ASSESSMENT OF SAFETY ............................................................................. 43 5.3
5.3.1 Physical examination .......................................................................................... 43
5.3.2 Vital Signs ............................................................................................................ 43
5.3.3 Safety laboratory parameters ................................
............................................ 43
5.3.4 Electrocardiogram .............................................................................................. 44
5.3.5 Other safety parameters..................................................................................... 44
5.3.6 Assessment of adverse events ............................................................................. 44
Definitions of AEs ................................................................
................................ 44 5.3.6.1
5.3.7 Adverse event collection and reporting ............................................................. 48
 

Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 9of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
OTHER ASSESSMENTS ................................................................................... 53 5.6
APPROPRIATENESS OF M EASUREMENTS .............................................. 53 5.7
6. INVESTIGATIONAL PLAN ............................................................................. 54
VISIT SCHEDULE ............................................................................................. 54 6.1
DETAILS OF TRIAL PRO CEDURES AT SELECTED VISITS ................. 54 6.2
6.2.1 Screening and run -in period(s) .......................................................................... 54
6.2.2 Treatment period(s) ............................................................................................ 55
6.2.3 Follow Up Period and Trial Completion ........................................................... 55
7. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE
............................................................................................................................... 57
STATISTICAL DESIGN - MODEL ................................................................. 57 7.1
NULL AND ALTERNATIVE HYPOTHESES ............................................... 57 7.2
PLANNED ANALYSES ..................................................................................... 58 7.3
7.3.1 Primary endpoint analyses ................................................................................. 59
7.3.2 Secondary endpoint analyses ............................................................................. 60
................................................................................ 60
7.3.4 Safety analyses ................................................................
..................................... 61
INTERIM ANALYSES ................................
...................................................... 62 7.4
HANDLING OF MISSING DATA ................................................................... 62 7.5
RANDOMISATION ........................................................................................... 62 7.6
DETERMINATION OF SAM PLE SIZE ......................................................... 63 7.7
8. INFORMED CONSENT, DA TA PROTECTION, TRIAL RECORDS ........ 65
TRIAL APPROVAL, PATI ENT INFORMATION, AND INFORMED 8.1
CONSENT ........................................................................................................... 65
DATA QUALITY ASSURANCE ................................
...................................... 66 8.2
RECORDS ........................................................................................................... 66 8.3
8.3.1 Source documents ............................................................................................... 66
8.3.2 Direct access to source data and documents..................................................... 66
8.3.3 Storage period of records ................................................................................... 67
LISTEDNESS AND EXPED
ITED REPORTING OF AD VERSE EVENTS 67 8.4
8.4.1 Listedness ................................................................
............................................. 67
8.4.2 Expedited reporting to health authorities and IEC / IRB............................... 67
STATEMENT OF CONFIDE NTIALITY ........................................................ 67 8.5
END OF TRIAL ................................................................
.................................. 67 8.6
PROTOCOL VIOLATIONS ............................................................................. 68 8.7
COMPENSATION AVAILAB LE TO THE PATIENT IN THE EVENT OF 8.8
TRIAL RELATED INJURY ................................
.............................................. 68
9. REFERENCES .................................................................................................... 69
PUBLISHED REFERENCES ............................................................................ 69 9.1
UNPUBLISHED REFERENC ES...................................................................... 72 9.2
10. APPENDICES ..................................................................................................... 73

Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 10of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
CRITERIA FOR HRCT/BI OPSY REVIEW ................................................... 73 10.1
CREATININE CLEARANCE ........................................................................... 73 10.2
ST GEORGE’S RESPIRAT ORY QUESTIONNAIRE (S GRQ) .................... 74 10.3
THE UCSD SHORTNESS O F BREATH QUESTIONNAIRE (UCSD - 10.4
SOBQ) .................................................................................................................. 80
EUROQOL -5D  (EQ -5D)................................................................................... 84 10.5
DLCO ................................................................................................................... 86 10.6
11. DESCRIPTION OF GLOBA L AMENDMENT(S) ......................................... 87
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 11of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
ABBREVIATIONS
AC Adjudication Committee
AE Adverse Event
AESI Adverse Event of Special Interest
ALP Alkaline Phosphatase
ALT
aPTT
ASAlanine T ransaminase
Activated Partial Thromboplastin Time
Aortic Stenosis
AST Aspartate T ransaminase
AUC Area under the Curve
AV Atrioventricular
BI
bid
BNPBoehringer Inge lheim
bis in die (twice dail y dosing)
Brain Natriuretic P eptide
cGMP Cyclic Guanosine Monophosphate
CI Confidence Interval
Cmax Maximum Plasma C oncentration
CML Local Clinical Monitor 
Cpre,ss
CRASteady  State Pre -dose P lasma C oncentrations
Clinical Research Associate
CRF
CROCase Report Form
Clinical Research Organization
CTCAE Common Terminology  Criteria for Adverse Events
CTP Clinical Trial Protocol
CTR
DBP
DDI
DILI
DLCOClinical Trial Report
Diastolic Blood P ressure
Drug -drug Interaction
Drug Induced Liver Injury
Carbon Monoxide Diffusion C apacity
DMC
DNAData Monitoring Committee
Desoxyribose Nucleic A cid
ECG Electrocardiogram
eCRF Electronic Case Report Form
EF
EOT
EudraCTEjection Fraction
End of Treatment
European Clinical Trials Database
FEV1 Forced Expiratory  Volume in 1 second
FGF(R) Fibroblast Growth Factor (Receptor)
FVC Forced Vital Capacity
GCP Good Clinical Practice
GGT Gamma -Glutam yl Transferase
GI
HRCT
IB
ICHGastrointestinal
High -resolution Computed T omograph y
Investigator’s Brochure
International Conference on Harmonization
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 12of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
IEC
IHSSIndependent Ethics Committee
Idiopathic Hypertrophic Subaortic S tenosis
INR International Normalised R atio
IPF Idiopathic Pulmonary  Fibrosis
IRB Institutional Review Board
IRT Interactive Response Technology
ISF
IUInvestigator Site File
International Units
i.v.
HbIntra venous
Haemoglobin
Kco Carbon Monoxide Transfer C oefficient
MACE Major Adverse Cardiovascular E vents
LDH
MedDRALactate Deh ydrogenase
Medical Dictionary  for Drug Regulatory  Activities
MMRM Mixed Effe cts Model for Repeated Measures
NAC N-acety lcysteine
nRTK Non-receptor Ty rosine Kinase
PaCO 2
PAH
PaO 2Partial Pressure of Carbon Dioxide
Pulmonary  Arterial Hy pertension
Partial P ressure of Oxygen
PDGF(R) Platelet Derived Growth Factor (Receptor)
PDE5 Phosphodiesterase T ype-5
PK Pharmacokinetic s
p.o.
PROper os (oral)
Patient Reported Outcomes
PT Prothrombin Time
REML
REPRestricted Maximum L ikelihood
Residual effect period, after the last dose of medication with measureable 
drug levels or pharmacodynamic effects still likely to be present
RNA
RTKRibonucleic Acid
Receptor T yrosine Kinase
SAE Serious Adverse Event
SBP
s.c.Systolic Blood Pressure
Subcutaneous
SGRQ St.George’s Respiratory  Questionnaire
SpO 2 Oxygen S aturation
SUSAR
tidSuspected Unexpected Serious Adverse Reactions
ter in die (3 times a day )
TSAP
TSHTrial Statistical Analy sis Plan
Thyroid Stimulating H ormone
ULN
UCSD SOBQ
VAUpper Limit of Normal
University  of California San Diego Shortness of Breath Questionnaire
Alveolar V olume
VEGF(R) Vascular Endothelial Growth Factor (Receptor)
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 13of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
1. INTRODUCTION
MEDICAL BACKGROUND 1.1
Idiopathic pulmonary  fibrosis (I PF) is a rare disease of unknown aetiology  that is 
characterized b y progressive fibrosis of the interstitium of the lung, leading to decreasing 
lung volume and progressive pulmonary  insufficiency  [P11-07084].
The course of the disease in individual patients is variable: some patients progress rapidly , 
others have periods of relative stability  punctuated by  acute exacerbations and others progress 
relativel y slowly. Acute exacerbations of IPF are events of respiratory deterioration of 
unidentified cause that occur in 5 –10% of patients annually  and are associated with a very  
poor outcome [ R12-2786]. 
IPF is most prevalent in middle aged and elderl y patients, and usually  presents between the 
ages of 40 and 70 years. The median life expectancy  in IPF patients after diagnosis is 2 to 3 
years [P11 -07084].
The latest update on clinical practice guideline for the treatment of IPF , jointly  issued in 2015
by the American Thoracic Society  (ATS), European Respiratory  Societ y (ERS), Japanese 
Respiratory  Societ y (JRS) and Latin American Thoracic Association (ALAT) has provided a 
conditional recommendation for treatment with nintedanib o r pirfenidone for the majority  of 
IPF patients, taking into account individual patient values and preferences [P15-07362]. 
Conventional I PF treatments such as n- acetylcysteine (NAC), corticosteroids, 
cyclophosphamide, cy clospor ine and azathioprine are not approved treatments for I PF, and 
their efficacy  is questionable or even harmful [ P15-07362; P12-06085; P14-07665]. Non-
pharmacological therapies such as pulmonary  rehabi litation and long -term oxy gen therap y 
are recommended for some patients, but their efficacy  in patients with IPF has not been 
established. L ung transplant has been shown to positively  impac t survival in patients with I PF
[R11-5086; R12-2785 ]. Although the number of patients transplanted due to I PF has 
increased steadil y over the last years, the scarce availability  of donor organs, as well as the 
comorbidities and advanced age preclude man y patients fro m referral to lung transplant [ R12-
3676 ; R12-3474].
Pirfenidone, a compound which demonstrated anti- fibrotic activit y in non -clinical models, 
was first licensed in Japan in 2008 based on two local trials which showed a reduced decline 
of vital capacity  under treatment with the compound [ R06-2070; R10-4316 ]. In the 
international Phase III CAPACI TY program, pirfenidone demonstrated efficacy  on the 
primary  FVC lung function endpoint in only one of two confirmatory  trials [ R11-4827]. The 
confirmatory  ASCEND Phase III trial met the primary  endpoint of change from baseline 
FVC % predicted [ R14-2103]. Pirfenidone is now licensed since February  2011 for the 
treatment of mild to moderate IPF in the EU and since October 2014 for the treatment of IPF 
in USA . It is also licensed in several other countries. 
Nintedanib is a small molecule intracellular t yrosine kinase inhibitor which has demonstrated 
anti-fibrotic and anti -inflammatory  activity  in preclinical models [ P08-08684 ; P14-02860]. 
The two replicate Phase III INPULSIS®trials and the Phase II TOMORROW trial 
consistently  showed positive results for the efficacy  of nintedanib 150 mg twice dail y versus 
placebo in patients with IPF. Both INPULSIS®trials showed that nintedanib reduced the 
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 14of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
annual rate of decline in FVC (mL/ year) b y approximately  50%, consistent with slowing 
disease progression [ P14-07514; P11-
11216]. Based on these three clinical trials, nintedanib 
was approved for the treatment of I PF in US Ain October 2014, in the EU in Jan uary 2015
and in Japan in July  2015 . It has been submitted for marketing authorization in other 
countries across the world.
Although nintedanib and pirfenidone can be considered a standard of care for patients 
diagnosed with I PF, there is an additional nee d to further characterize their profile, including 
their use in special populations not previously  studied or in potential combination treatment 
regimens to enhance efficacy .
DRUG PROFILE 1.2
1.2.1 Nintedanib
Nintedanib is a small molecule that inhibits a distinct spectrum of receptor ty rosine kinases 
(RTKs) and non- receptor ty rosine kinases (nRTKs) at pharmacologicall y relevant 
concentrations. Among them, FGFR (fibroblast growth factor/receptor), PDGFR (platelet 
derived growth factor/receptor) and VEGFR (vascular e ndothelial growth factor/receptor) 
have been implicated in IPF pathogenesis. Nintedanib binds competitively  to the adenosine 
triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signalling 
which is crucial for the proliferation , migration, and transformation of fibroblasts 
representing essential mechanisms of the IPF pathology  [P08-08684; P14-02860]. 
A soft gelatin capsule formulation of nintedanib is used in humans. Maximum plasma 
concentrations occur between 2 -4 hours after oral administration. Steady  state is reached at 
the latest within one week of dosing. After food intake, a trend towards an increased s ystemic 
exposure (around 15 to 20%) and a delay ed absorptio n is observed compared to 
administration under fasted conditions. Nintedanib is recommended to be taken with food. 
Nintedanib is preferentially  distributed in plasma with a blood to plasma ratio of 0.87 and the 
terminal half -life found in healthy  volunteer s is in the range of 7 to 19 h. The absolute 
bioavailability  of nintedanib is slightly  below 5%. Nintedanib is mainly  eliminated via faeces.
Co-administration of nintedanib with the P- glycoprotein (P -gp) inhibitor ketoconazole 
increased exposure to ninteda nib by  60-70% based on area under the curve (AUC) and by  
80% based on a maximum measured concentration of the anal yte in plasma (Cmax) in a 
dedicated drug -drug interaction (DDI) study . Patients taking potent P -gp inhibitors ( e.g.
ketoconazole, ery throm ycin or cy closporine) should be monitored closel y for tolerability of 
nintedanib. 
In a DDI stud y with the P -gp inducer rifampicin, exposure to nintedanib decreased to 50.3% 
based on AUC and to 60.3% based on Cmax upon co-administration with rifampicin 
compare d to administration of nintedanib alone. Since potent P -gp inducers may  decrease 
exposure to nintedanib, selection of alternate treatment with no or minimal P -gp induction 
should be considered. 
The clinical efficacy  of nintedanib has been studied in over 1400 patients with I PF in one 
phase II dose finding study  (TOMORROW) including four different doses of nintedanib, and 
two replicate phase III (INPUL SIS®1 and 2) trials. These were randomized, double -blind, 
placebo -controlled studies comparing treatment w ith nintedanib twice daily  to placebo for 52 
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 15of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
weeks. A statisticall y significant reduction in the annual rate of decline of FVC (in mL) was
demonstrated in patients receiving nintedanib 150 mg bid compared to patients receiving 
placebo. The treatment effect on FVC was consistent in all 3 studies, i.e. a relative reduction 
of approximately  50% between nintedanib and placebo. Furthermore nint edanib 150 mg bid 
significantl y reduced the risk of first acute exacerbation compared with placebo in 
INPULSIS®-2 and in the TOMORROW trial, and  reduced the risk of adjudicated 
confirmed/suspected acute exacerbations by 68% in a pre -specified sensitivity  anal ysis of  
pooled data from the INPULSIS®trials, supporting the effect of nintedanib on slowing 
disease progression [ P14-07514; P11-11216].
The safet y profile of nintedanib has been investigated comprehensivel y. The proportion of 
patients with serious adverse events was similar in the nintedanib and placebo groups . 
The risks of treatment with nintedanib in adult patients are primarily  related to the 
gastrointestinal tract (nausea, vomiting, diarrh oea, abdominal pain) and to increases in liver 
enzy mes (aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline 
phosphatase (ALP), gamma -glutam yl transferase (GGT) and bilirubin ). The most frequentl y 
reported adverse event was diarrh oea which was mild to moderate in intensity  for the vast 
majority  of patients and lead to treatment discontinuation in less th an five percent of patients 
treated with nintedanib. Also weight decrease and decreased appetite have frequently  been 
reported in studies with nintedanib. 
Risks of nintedanib treatment also include arterial hy pertension, gastrointestinal perforations, 
thromboembolism , pancreatitis, thrombocytopenia and bleeding. Patients treated with full-
dose anticoagulation or at known risk for bleeding were excluded from the INPULSIS®trials. 
This has led to recommendations stating that patients at known risk for bleedi ng should be 
treated with nintedanib only  if the anticipated benefit outweighs the potential risk. Although 
cardiac disorders AEs were balanced between the nintedanib and placebo groups, a higher 
proportion of patients in the nintedanib groups had my ocardi al infarctions. Conversel y, a 
lower proportion of patients in the nintedanib groups had other ischemic heart disease. ‘Other 
ischemic heart disease’ was a pre -defined category  including terms such as coronary  artery  
disease, angina pectoris, coronary  angio plasty , coronary  artery  stenosis, myocardial ischemia, 
coronary  artery  stent insertion, electrocardiogram (ECG) ST segment depression. The clinical 
significance of this finding is unknown, and further observation is needed.
For patients finalizing the 52 week stud y treatment in the TOMORROW and INPUL SIS®
trials, participation in open label extension trials (1199.35 and 1199.33) was offered. Long 
term treatment in these still ongoing open label extension trials confirm sthe safet y profile 
observed in the ph ase II and III trials [P15-09876
].
Nintedanib has also demonstrated efficacy  and tolerable safet y in patients with non -small cell 
lung cancer who failed first treatment [ P11-00203], as well as in pa tients with advanced renal 
cell cancer [ P13-06268], ovarian cancer [ P11-10116] and hepatocellular carcinoma [ P13-
12693 ]. Furthermore, nintedanib is also being investigated in other oncological indications, 
such as mesothelioma [ P14-08020 ].
For a more detailed description of the drug profile refer to the current Investigator’s Brochure 
(IB) [ U07-1248] which is included in the Investigator Site File (ISF).
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 16of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
1.2.2 Sildenafil
Sildenafil is an inhibitor of cyclic guanosine monophosphate (cGMP )specific 
phosphodiesterase t ype-5 (PDE5) in the smooth muscle of the pulmonary  vasculature, where 
PDE5 is responsible for degr adation of cGMP. Sildenafil, therefore, increases cGMP within 
pulmonary  vascular smooth muscle cells resulting in relaxation. This can lead to vasodilation 
of the pulmonary  vascular bed and, to a lesser degree, vasodilatation in the sy stemic 
circulation.
Sildenafil is rapidly  absorbed after oral administration, with a mean absolute bioavailability  
of 41% (25 –63%). Maximum observed plasma concentrations are reached within 30 to 120 
minutes (median 60 minutes) of oral dosing in the fasted state. Sildenafil a nd its major 
circulating N -desmethy l metabolite are both approximately  96% bound to plasma proteins. 
Protein binding is independent of total drug concentrations. N-desmeth yl metabolite has a 
phosphodiesterase selectivity  profile similar to sildenafil and a n in vitro potency  for PDE5 
approximately  50% of the parent drug. Both sildenafil and the active metabolite have 
terminal half-lives of about 4 hours. After oral administration, sildenafil is excreted as 
metabolites predominantly in the faeces (approximate ly 80% of the administered oral dose) 
and to a lesser extent in the urine (approximately  13% of the administered oral dose).
Sildenafil metabolism is principally  mediated by  the CYP3A (major route) and CYP2C9 
(minor route) cytochrome P450 isoforms. Therefo re, inhibitors of these isoenzy mes may  
reduce sildenafil clearance and inducers of these isoenzy mes may  increase sildenafil 
clearance. 
Concomitant use of sildenafil with ritonavir and other potent CYP3A inhibitors is 
not recommended.
Sildenafil is indicated for the treatment of Pulmonary  Arterial Hy pertension ( PAH )in adults 
to improve exercise ability and delay  clinical worsening. The efficacy  of sildenafil was 
evaluated in four phase 3 short term studies (12 to 16 weeks), and include d predominatel y 
patients with New York Heart Association (NYHA) Functional Class II –III symptoms. 
Etiologies were idiopathic (71%) or associated with connective tissue disease (25%). Based 
on the identification of different mechanistic pathway s involved in the pathogenesis of 
pulmonary  arterial hy pertension, i.e. the nitric oxid, endothelin and prostaglandin pathway s,
increasing evidence suggest
s a role for sequential or upfront combination treatment in 
patients with PAH [ R15-5447]. However, the effects of combination treatment of sildenafil 
with endothelin antagonists like macicentan or bosentan on morbidity  and mortality  are 
mixed [R15-5445; R15-5446 ].
Silden afil(20 mg ti d) has also been studied in a 12 week double -blind placebo -controlled
randomized trial followed by  a 12 week period of open-label treatment which enrolled 180 
IPF patients with advanced lung function impairment (STEP- IPF). Although this study  met 
significant differences in some secondary  endpoints such as quality  of life, it failed to meet its 
primary  outcome of change in 6 -minute walk distance of ≥ 20% at week 12 [R12-
3686].
Safety  data of sil denafil in adults were obtained from a 12- week, placebo -controlled clinical 
study  and an open -label extension study  in 277 patients with PAH, WHO Group I . The 
overall frequency  of discontinuation in patients treated with sildenafil on 20 mg three times a 
day was 3% and was the same for the placebo group. Most common adverse reactions greater 
than or equal to 3% and more frequent than placebo were epistaxis, headache, dy spepsia, 
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 17of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
flushing, insomnia, ery thema, dy spnea, and rhinitis. Adverse reactions were gene rally 
transient and mild to moderate in nature.
Potential risks of treatment with sildenafil include hy potension, worsening of pulmonary  
veno -occlusive disease, epistaxis, visual loss, hearing loss, priapism and vaso -occlusive crisis 
in patients with pulm onary  hypertension secondary to sickle cell disease .
In the STEP -IPF study  approximately  90% of patients in each group (sildenafil or placebo) 
had at least one adverse event with the most common being dyspnoea , cough and progression 
of IPF during the doubl e-blind 12 weeks period. The proportion of serious adverse events 
was also similar between groups (15% in sildenafil vs. 16% in placebo) without significant 
between -group differences in the occurrence of specific serious adverse events [ R12-3686].
Sildenafil is also indicated in adult men with erectile dy sfunction with a recommended dose 
of50 mg taken as needed approximately one hour before sexual activity .This dose will not 
be used in this study .
For a more detailed description of the drug profile refer to the current local Prescribing 
Information or Summary of Product Characteristics which is included in the Investigator Site 
File (ISF).
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 18of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
2. RATIONALE, OBJECTIVE S, AND BENEFIT - RISK 
ASSESSMENT
RATIONALE FOR PERFOR MING THE TRIAL 2.1
Until recentl y, IPF was essentially an untreatable disease. With the availability  of specific 
antifibrotic drugs like nintedanib and pirfenidone, a major advance in the management of IPF 
has been achieved. Although both drugs are approved for the treatment of all I PF patients 
(with the exception of pirfenidone in Europe and other countries where it is approved onl y for 
“mild to moderate IPF”) , patients with advanced lung function impairment have been 
typicall y excluded from the most recent clinica l trials in I PF.
In contrast to patients with more preserved lung function, abnormalities of the pulmonary  
vasculature due to continuous destruction of the vasculature b y fibrosis and aberrant vascular 
remodeling , leading to decreased levels of resting and exercise -induced production of nitric 
oxide , are more common in patients with advanced lung function impairment, specificall y in 
patients with advanced impairment in diffusion capacit y. Since nitric oxide is a potent 
pulmonary  vasodilator, reduced levels are associated with pulmonary  vasoconstriction and 
impaired gas exchange.
Nintedanib is an inhibitor of ty rosine kinases (including the PDGF, VEGF and FGF 
receptors). By  inhibiting these receptors, nintedanib regulates cellular proliferation, survival, 
migration and differentiation, processes which are involved in the profibrotic process of IPF
[P08-08684; P14-02860 ]. The phase II and III clinical studies showed that nintedanib slowed 
IPF disease progression by  reduc ingthe annual lung function decline and potentially  the risk 
for acute exacerbations , however no clinically  relevant beneficial effect on health related 
quality  of life or other patient -related outcomes measures wasobserved [ P14-07514; P11-
11216 ].
Sildenaf il,a PDE5 inhibitor approved for the treatment of PAH ,stabilizes the second 
messenger of nitric oxide (cGMP) which leads to pulmonary  vasodilation. Althoug h the 
STEP -IPF trial failed to meet its primary  outcome of change in 6-minute walk distance of ≥ 
20% at week 12, it showed promising results in secondary  endpoints with clinically  
significant differences in the degree of d yspnea and quality  of life, as wel l as in gas exchange 
parameters [R12-3686].
Combining these two drugs with different molecular targets might ultimately provide 
additional benefits to patients with IPF and advanced lung function and gas exchange 
impairment : nintedanib by slowing the disease progression and sildenafil by impacting 
patient relevant outcomes such as quality  of life and dy spnea .
Given the limitations of the STEP -IPF study ,including the low number of patients , further 
data is required in order to confirm the s ymptomatic benefits of sildenafil. In addition, this 
trial will allow the collection of safet y and tolerability  data of the combined treatment of 
nintedanib and sildenafil as well as of nintedanib alone ina population with advanced disease 
which has been ty pically  excluded from the most recent clinical trials in I PF.
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 19of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
TRIAL OBJECTIVES 2.2
The primary  objective is to assess efficacy and safety  of concomitant treatment with 
nintedanib and sildenafil in I PF patients with advanced lung function impai rment .
A further important objective of the trial is to enlarge the existing nintedanib mono -therap y
database with safet y and tolerability data in this population .
In addition, t he effect of nintedanib and sildenafil on biomarkers related to IPF 
pathophy siology  will be assessed to increase understanding of the mode of action of both 
compounds.
BENEFIT - RISK ASSESSMENT 2.3
All patients in this trial will be treated with nintedanib. As described in section 1 , patients 
with I PF m ay benefit from lesser decline in lung function and hence slower disease 
progression as a result of treatment with nintedanib. I n addition, nintedanib significantl y 
reduced the risk of a first acute exacerbation in 2 out of 3 clinical trials [ P11-11216, P14 -
07514 ].
Half of the patients in this trial will be treated with sildenafil in addition to nintedanib. In the 
STEP -IPF trial, sildenafil showed promising results in sy mptomatic or patient- related
endpoints such as d yspnea and health -related quality  of life [ R12-3686].
Although currentl y unknown, concomitant treatment of both drugs may  ultimately  be found 
to add further benefits to patients. 
The safet y profile of nintedanib and sildenafil isdescribed in section 1.2 .
The most common side effects of nintedanib are of gastrointestinal nature (diarrh oea, nausea, 
vomiting, abdominal pain), as well as liver enzy me elevations. Side effects are generally  mild 
to moderate in nature. In case of side effects, s ymptomatic treatment, dose adjustments and/or 
interruptions of nintedanib should be considered to allow for resolution of the sy mptoms 
(section 4.2.1 ).
Risks of nintedanib treatment also include arterial hy pertension, gastrointestinal perforations, 
thromboembolism , pancreatitis, thrombocytopenia and bleeding. Therefore, patients requiring 
full dose concomitant anticoagulation, fibrinolysis or high -dose antiplatelet therapy  will be 
excluded from this trial.
The mode of action of nintedanib indicates a high potential for teratogenicity and/or 
embry otoxicity , including fetotoxicity /lethalit y. In women of childbearing potential receiving 
nintedanib, contraceptive measures must be employ ed 28 day s before treatment initiation, 
during the treatment and for a period of 3 months after last drug intake.
Themost common side effects of sildenafil are epistaxis, headache, dy spepsia, flushing, 
insomnia, ery thema, dy spnea and rhinitis. Side effects are generall y mild to moderate in 
nature. In case of side effects, sy mptomatic treatment and/or interruption of sildenafil should 
be considered to allow for resolution of the s ymptoms ( section 4.2.1 ).
Potential risks of treatment with sildenafil include hy potension, worsening of pulmonary  
veno -occlusive disease, epistaxis, visual loss, hearing loss, priapism and vaso -occlusive crisis 
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 20of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
in patients with pulmonary  hypertension secondary to sickle cell disease . Patients at higher 
risk for these conditions are excluded from this trial.
Clinical data o n the pharmacokinetics of nintedanib and sildenafil when given in combination 
is not available. Based on the known metabolic properties of both compounds, the likelihood 
of a pharmacokinetic drug -drug interaction is considered to be low. Nintedanib and its
metabolites, BIBF 1202 and BIBF 1202 glucuronide, did not inhibit or induce CYP enzy mes 
in vitro.
It is currentl y unknown if the co- administration of both drugs will result in additional side 
effects. To minimize this risk, s afety monitoring in this trial will consist of regular visits to 
the investigational site, blood analy ses and specific monitoring procedures to follow -up 
potential hepatic enzy me elevation. In addition, an independent data -monitoring committee 
(DMC) will review the safet y data at specified intervals during the study  conduct (refer to 
section 3.1.1 ).
Overall, the clinical safety profile of both nintedanib and sildenafil as established during the 
previous clinical trials is interpreted as favourable for the intended indication of I PF.
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 21of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
3. DESCRIPTION OF DESIG N AND TRIAL POPULATI ON
OVERALL TRIAL DESIGN AND PLAN 3.1
This is a multi -centre, multi -national, prospective, randomised, double -blind , parallel -group 
clinical trial to investigate the efficacy  and safet y of nintedanib when co -administered with 
sildenafil, compared to treatment with nintedanib alone, in patients with IPF and advanced 
lung function impairment .
A total of approximately  250 patients will be randomised in a blinded fashion to nintedanib
150 mg bid co-administered with sildenafil 20 mg tid or to nintedanib 150 mg bid co-
administered with placebo matching sildenafil . Patients will be stratified at randomization by  
the presence of anyechocardiographic signs indicative of right heart dy sfunction includ ing 
right ventricular h ypertrophy  and right ventricular or atrial dilatation (as described in sections 
6.2.1 and7.6). Randomized treatment will last 24 weeks. During the randomized treatment 
period, dose reductions and/or temporary  interruptions of nintedanib , as well as drug 
interruption of sildenafil/matching placebo, are allowed to manage adverse events ( section 
4.2.1 ).The planned follow- up period for patients after study  treatment completion will be 
four weeks. Patients who prematurel y discont inue all study  drugs ,will be invited to attend all 
visits as planned until week 24 (v isit 7 ).
Each patient’s participation in the trial is estimated to last approximately  32weeks (from visit 
1).
Figure 3.1:1 Trial design scheme
3.1.1 Administrative structure of the trial
The sponsor of this trial is Boehringer Ingelheim (BI).

Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 22of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
BIhas appointed a Trial Clinical Monitor, responsible for coordinating all required activities,
in order to 
- manage the trial in accordance with applicable regulations and internal SOPs,
-direct the clinical trial team in the preparation, conduct, and reporting of the trial,
-ensure appropriate training and information of local clinical monitors (CML), Clinical 
Research Associates ( CRA s), and Investigator s of participating countries.
Data Management , Pharmacokinetic and Statistical Evaluation will be d one by  BI according 
to BI SOPs.
Tasks and functions assigned in order to organi se, manage, and evaluate the trial will be 
defined according to BI SOPs. A list of responsible persons and relevant local information
can be found in the I SF.
Additional information for Japan only :A list of responsible persons and relevant local 
information (as protocol reference, if applicable) can be found in the ISF.
A Coordinating Investigator will be nominated and will be responsible to coordinate 
Investigator s at different centres participating in this multicentre trial. Tasks and 
responsibilities will be defined in a contract. Relevant documentation on the participating 
(Principal) I nvestigators and other important participants, including their curricula vitae, will 
be filed in the ISF.
Sites selected for participation will consist of specialized referral centres experienced in t he 
management of IPF.
A DMC, independent of the sponsor , will be established to assess the progress of the clinical 
trial, including an unblinded safet y assessment at specified intervals, and to recommend to 
the sponsor whether to continue, modify , or stop the trial. Measures are in place to ensure 
blinding of the sponsor and all other trial participants. 
All death cases will be assessed (to evaluate the primary  cause of death) ,as well as 
all 
adverse events categorized as major adverse cardiovascular events (MACE) and all acute IPF 
exacerbations (based on written clinical reports, for diagnostic confirmation) by  an 
independent Adjudication Committee (AC) , in a blinded manner before data base lock. The 
tasks and responsibilities of the DMC and the AC will be specified in a charter. 
The DMC and the AC will maintain written records of all its meetings.
A central laboratory  will perform all protocol specified blood anal ysis of the trial. 
An IRT will perform randomization of patients and ensure appropriate distribution of trial 
medication to sites during the trial. 
A central vendor will provide spirometers for the complete duration of the trial. 
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 23of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
DISCUSSION OF TRIAL DESIGN, INCLUDING TH E CHOICE OF 3.2
CONTROL GROUP(S)
In the STEP -IPF trial sildenafil has been shown to improve patient -relevant outcomes such as 
dyspnea and quality  of life in patients with advanced lung function impairment at 12 weeks
[R12-3686]. In order to confirm these findings and a potential added benefit of sildenafil 
when added to current standard of care , a double -blind, parallel group trial design was 
selected where half of the patients will be treated with sildenafil and half of the patients will 
be treated with plac ebo m atching sildenafil. All patients will be treated with nintedanib as 
background therap y considered usual care in patients with I PF. 
The randomized treatment period duration of 24weeks is thought to be adequate to evaluate 
if the efficacy  is maintained aft er the primary  endpoint assessment at 12 weeks. In addition it
is considered an appropriate treatment duration to allow the collection of safety  and 
tolerability data of concomitant treatment of nintedanib and sildenafil, as well as collection of 
additiona l safet y data for nintedanib monotherap y in a population with a more advanced lung 
function impairment in comparison to the population enrolled in the Phase II and III 
TOMORROW and INPULSIS®trials.
The frequency  of visits will allow close monitoring of em ergent adverse events as well as 
control of liver enz yme values consistent with the recommendations of the prescribing 
information of nintedanib .
To obtain further efficacy  and safet y information on the concomitant treatment of nintedanib 
and sildenafil , lung function tests, clinical laboratory  tests and electrocardiograms will be 
performed. Data on discontinuations and death will be recorded.
SELECTION OF TRIAL P OPULATION 3.3
A total of approximately  250 patients with an I PF diagnosis and advanced lung function 
impairment will be randomized. Approximately  80sites are each expected to include 
approximately 3patients. 
A log of all patients enrolled into the trial(i.e. who have signed informed consent) will be 
maintained in the I SF at the investigational site irrespective of whether they  have been treated 
with investigational drug or not.
3.3.1 Main diagnosis for trial entry
Any patients diagnosed with I PF and who comply  with eligibility  requirements may  qualify  
for participation in the trial. 
Please refer to section 8.3.1 (Source Documents) for the documentation requirements 
pertaining to the in -and exclusion criteria.
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 24of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
3.3.2 Inclusion criteria
1.Written informed consent consistent with I CH-GCP and local laws, signed prior to 
any study  procedures being performed (i ncluding any  required washout);
2.Male or female patients aged ≥40 y ears at visit 1;
3. A clinic al diagnosis of IPFwithin the last 6years before visit 1, based upon the 
ATS/ERS/JRS/AL AT 2011 guideline [ P11-07084
];
4.Combination of high-resolution computed tomography (HRCT )pattern, and if 
available, surgical lung biopsy  pattern consistent with a diagnosis of IPF (see 
appendix 10.1) as assessed by  the investigator based on a HRCT scan performed 
within 18 months of visit 1;
5.DLCO(corrected for Hb) ≤ 35% predicted of normal at visit 11.
3.3.3 Exclusion criteria
1. Previous enrolment in this trial;
2.ALT, AST > 1.5 fold upper l imit of normal (ULN) at visit 11;
3.Total bilirubin > 1.5 fold ULN at visit 11;
4.Relevant airway s obstruction (i.e. pre -bronchodi lator FEV1/FVC <0.7 at visit 11);
5.History  of m yocardial infarction within 6 months of visit 1 or unstable angina within 
1 month of visit 1 ;
6.Bleeding Risk:
Known genetic predisposition to bleeding ;
Patients who require fibrinolysis, full -dose therapeutic anticoag ulation (e.g. 
vitamin K antagonists, direct thrombin inhibitors , heparin, hirudin, etc.) or 
high dose antiplatelet therap
y2;
History  of haemorrhagic central nervous s ystem (CNS ) event within 12 
months prior to visit 1;
History  of haemopt ysis or haematuria, active gastro -intestinal bleeding or 
ulcers and/or major injury or surgery  within 3 months prior to visit 1;
International normalised ratio (INR) > 2 at visit 11;
Prothrombin time (PT) and activated partial thromboplastin time ( aPTT) > 
150% of institutional ULN at visit 11;
7.Planned major3surgery  during the trial participation, including lung transplantation , 
major abdominal or major intestinal surgery ;
8.History  of thrombotic event (including stroke and transient ischemic atta ck) within 12 
mont hs of visit 1;
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 25of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
9.Creatinine clearance < 30 mL /min calculated by  Cockcroft–Gault formula (appendix 
10.2) at visit 11;
10.Presence of aortic stenosis (AS) per investigator judgement at visit 1 ;
11.Severe chronic heart failure: defined b y left ventricular ejection fraction (EF) < 25%
per investigator judgement at visit 1 ;
12.Presence of idiopathic h ypertrophic subaortic stenosis (I HSS) per investigator 
judgement at visit 1 ;
13.Second- degree or third -degree atrioventricular (AV) block on electroca rdiogram
(ECG) per investigator judgement at visit 1 ;
14.Hypotension (s ystolic blood pressure [SBP] < 100 mm Hg or diastolic blood pressure
[DBP] < 50 mm Hg) (symptomatic orthostatic hypotension) at visit 1;
15.Uncontrolled s ystemic hy pertension (SBP > 180 mmHg or DBP > 100 mmHg) at visit 
11;
16.Known penile deformities or conditions (e.g., sickle cell anemia, multiple my eloma, 
leukemia) that may  predispose to priapism ;
17.Retinitis pigmentosa ;
18.History  of vision loss ;
19.History  of nonarteritic ischemic optic neuropathy ;
20.Veno -occlusive disease;
21.History  ofacute IPF exacerbation or respiratory  infection within 8 weeks of visit 2.
22.Treatment with nitrates, n-acetylcysteine , pirfenidone, azathioprine,
cyclophosphamide, cy closporine ,prednisone >15 mg dail y or >30 mg every  2 day s 
OR equivalent dose of other oral corticosteroids as well as an y investigational drug 
within 4 weeks o f visit 2;
23. Treatment with prostaglandins (e.g., epoprostenol, treprostinil), endothelin-1 
antagonists (e.g., bosentan, sitaxsentan, amb risentan), phosphodiesterase inhibitor s
(e.g., sildenafil, tadalafil, vardenafil) or a stimulator of guany latcy clase (e.g., 
riociguat )within 4weeks of visit 2;
24. Treatment with potent CYP3A4 inhibitors such as ketoconazole, itraconazole and 
ritonavir withi n 4weeks of visit 2;
25.Supplementation with L -arginine and concurrent use of grapefruit juice or St John’s 
wort within 4 weeks of visit 2;
26. Treatment with the reduced dose of nintedanib (100 mg bid) within 4 weeks of visit 
24;
27.Permanent discontinuation of nintedanib in the past due to adverse events considered 
drug-related;
28.Known hy persensitivity  or intolerance to nintedanib, sildenafil , galactose, peanut or 
soya or any other components of the study medication;
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 26of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
29. A disease or condition which in the opinion of the investigator may  interfere with 
testing procedures or put the patient at risk when participating in this trial ;
30.Alcohol or drug abuse which in the opinion of the treating ph ysician would interfere 
with treatment ;
31.Women who are pregnant, nursing, or who plan to become pregnant while in the trial ;
32. Women of childbearing potential5not willing or able to use highl y effective methods 
of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per 
year when used consistently  and correct ly6;
33.Patients not able to understand and follow study  procedures including completion of 
self-administered questionnaires without help.
34.Patients with underly ing chronic liver disease (Child Pugh A, B or C hepatic 
impairment)
1Laboratory  parameter s, blood pressure and lung function tests may be re -tested 
within the permitted timeframe, if found abnormal at Visit 1 and thought to be a 
measurement error or was the result of a temporary and reversible medical condition.
2 Exceptions: prophy lactic low dose heparin or heparin flush as needed for 
maintenance of an indwelling intravenous device (e.g., enoxaparin 4000 IU 
subcutaneous ( s.c.)perday) and prophy lactic use of antiplatelet therap y (e.g., acet yl 
salicy lic acid up to 325 mg/d, and/ or clopidogrel at 75 mg/d, and/ or equivalent doses 
of other antiplatelet therapy ).
3 Definition of major is per investigator judgement.
4 Patients on treatment with nintedanib 150 mg bid during the screening period are 
eligible. However if an interruption or reduction of dos e is required during the 
screening period or at time of randomization, the patient will no longer be eligible.
5Women of childbearing potential are defined as: Any female who has experienced 
menarche and does not meet the criteria for "women not of chi ldbearing potential” 
defined as: Women who are postmenopausal (12 months with no menses without an 
alternative medical cause) or who are permanently sterilized (e.g., tubal occlusion, 
hysterectom y, bilateral oophorectom y or bilateral salpingectomy).
6A list of contraception methods meeting these criteria is provided in the patient 
information .
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 27of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
3.3.4 Removal of patients from therap y or assessments
Removal of individual patients 3.3.4.1
An individual patient is to be withdrawn from trial participation if the patient withdraws 
consent for trial participation, without the need to justify  the decision.
An individual patient is to be withdrawn from all trial drugs (nintedanib and 
sildenafil /matching placebo ) if:
The patient withdraws consent for st udy treatment , without the need to justify  the 
decision;
The patient needs to take concomitant drugs that interfere with the investigational 
product s (section 4.2.2 );
The patient can no longer be treated with trial medication for other medical reasons 
(such as surgery , adverse events, other diseases, or pregnancy );
If a patient becomes pregnant or pregnancy  is suspected during the trial, the patient will 
be permanently  discontinued from study  treatment and will be followed up until birth or 
otherwise te rmination of pregnancy , please see section 5.3.7 .
The patient experiences s igns or s ymptoms of acute my ocardial ischemia or stroke;
The patient experiences signs of hepatic injury , defined as one of the following:
ALT and/or AST ≥ 8fold ULN
ALT and/or AST ≥ 3 fold ULN and total bilirubin ≥ 2 fold ULN
ALT and/or AST ≥ 3 fold ULN and unexplained INR > 1.5
ALT and/or AST ≥ 3 fold ULN and unexplained eosinophilia (> 5%)
ALT and/or AST ≥ 3 fold ULN and appearance of fat igue, nausea, vomiting, 
right upper abdominal quadrant pain or tenderness, fever and/or rash.
For potential drug induced liver injury  (DILI) follow up requirements please see sections
4.2.1.3 and 5.3.6.1. 
Treatment with nintedanib must be permanentl y discontinued in the following situations:
In the opinion of the investigator, the patient experiences u nacceptable toxicity due to 
nintedanib despite dose adjustments and supportive care;
Gastrointestinal perforation;
Major surgery  including abdominal or intestinal surgery ;
Signs or s ymptoms of deep vein thrombosis or pulmonary  embolism;
Treatment interruption longer than 4 weeks (continuous) .
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 28of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
In addition, permanent discontinuation of nintedanib should be considered in the following 
situations:
Patient who require sfull dose therapeutic anticoagulation or high dose antiplatelet 
therap y;
Increased risk of bleeding (e.g., gross/ frank haemopty sis or haematuria, active gastro-
intestinal bl eeding or ulcers).
In such cases, continuation of nintedanib should be discussed with the patient and the 
decision based on an individual benefit -risk assessment documented in the source data. 
Treatment with sildenafil /matching placebo must be permanentl y discontinued in the 
following situations:
In the opinion of the investigator, the patient experiences unacceptable toxicity  due to 
sildenafil despite supportive care;
Hypotension (SBP < 100 mmHg or DBP < 50 mmHg) accompanied b y symptoms ;
In the event of any sudden visual defect ;
Prolonged erections and priapism ;
Treatment interruption longer than 4 weeks (continuous) .
If a patient discontinues all study  drugs (nintedanib and sildenafil/matching placebo), he/she 
will undergo the procedures for earl y trea tment discontinuation and will be invited to attend 
all planned study  visits until week 24 as outlined in the flow chart .
For all patients the reason for withdrawal (e.g. adverse events) must be recorded in the 
electronic case report form ( eCRF ). These data will be included in the tri al database and 
reported.
Discontinuation of the trial by  the s ponsor 3.3.4.2
Boehringer Ingelheim reserves the right to discontinue the trial overall or at a particular trial 
site at any  time for the following reasons:
1. Failure to meet expected enrolment goals overall or at a particular trial site
2.Emergence of an y efficacy /safet y information invalidating the earlier positive benefit -
risk-assessment that could significantl y affect the continuation of the trial
3.Violation of good clinical practice (GCP), the clinical trial protocol (CTP), or the contract 
disturbing the appropriate conduct of the trial
The Investigator / the trial site will be reimbursed for reasonable expenses incurred in case of 
trial termination (except in case of the third reason).
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 29of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
4. TREATMENTS
TREATMENTS TO BE ADM INISTERED 4.1
4.1.1 Identity  of BI investigational product and comparator product
Table 4.1.1:1 Nintedanib 
Substance: Nintedanib (Ofev®)
Pharmaceutical formulation: Soft gelatin ecapsule
Source: BI Pharma GmbH & Co.KG
Unit strength: 150 mg, 100 mg
Posology 1 capsule, bid
Route of administration: Oral (swallowed)
Table 4.1.1:2 Sildenafil and placebo matching sildenafil
Substance: Sildenafil Placebo
Pharmaceutical formulation: Capsules Capsules
Source:BI Pharma GmbH & 
Co.KG tablets for 
overencapsulation 
sourced from PfizerBI Pharma GmbH & 
Co.KG
Unit strength: 20 mg Not applicable
Posology 1capsule , tid 1capsule , tid
Route of administration: Oral (swallowed) Oral (swallowed)
4.1.2 Method of assigning patients to treatment groups
Patient randomization to treatment groups will be determined b y an IRT system. Access to
the randomization code will be controlled and documented. All necessary  instructions for
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 30of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
using the IRT s ystem will be described in a user guide/manual, a copy  of which will be
available in the ISF.
Atvisit 2 , eligible patients will be randomised via IRT to one of the two treatment groups.
Patients will have an equal chance of being randomised to nintedanib co-administered with 
sildenafil or to nintedanib co-administered with placebo matching sildenafil.
4.1.3 Selection of doses in the trial
Nintedanib: A dose of 150 mg bid (total dail y dose of 300 mg) was selected for this trial as 
this is the recommended dose based on prescribing information in participating countries.  
Dose adjustments are permitted as per section 4.1.4.1 and section 4.2.1 .
Sildenafil: A dose of 20 mg tid (total daily  dose of 60 mg) was selected for this trial as thi s is 
the recommended dose for the approved indication of PAH based on the prescribing 
information in participating countries. This was also the dose studied in I PF patients in the 
STEP -IPF stud y [R12-3686]. No dose adjustment is allowed during this study .
4.1.4 Drug assignment and administration of doses for each patient
Drug is dispensed b y the investigator, stud y coordinator or pharmacist, depending on the site 
structure. IRT will be used to assign appropriate treatment kits to each patient. 
To ensure patients receive adequate supply  of study  medication, kits will be dispensed at 
clinic visits in quantities outlined in table 4.1.4:1
Table 4.1.4:1 Quantity  of medication kits dispensed:
Visit Nintedanib KitSildenafil / Matching 
Placebo Kit
2 1 1
3 1 1
4 1 1
5 3 3
Nintedanib 4.1.4.1
Treatment with nintedanib will consist of 1 capsule twice dail y (bid). 
The first administration of nintedanib will be taken in the clinic at visit 2. 
The patients should swallow nintedanib unchewed with a glass of water (250mL ) and 
should observe a dosing interval of 12 hours.
Nintedanib should be taken at the same time every day  between 06:00 and 11:00 in 
the morning and between 18:00 and 23:00 in the evening.
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 31of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Because nintedanib may  cause stomach di scomfort, it is recommended to be taken at 
the end of a meal. 
If a dose of nintedanib is missed, administration should resume at the next scheduled 
time at the recommended dose.  Double doses should not be taken to make up for 
forgotten capsules. 
Dose ad justment of nintedanib is allowed to manage adverse events : 300 mg dail y (150 mg 
bid) may  be reduced to 200 mg dail y (100 mg bid) .For additional details please refer to 
section 4.2.1 .
Dose reductions or re -escalation of nintedanib must be done in the clinic at a dose adjustment 
visit (refer to the flow chart ), as a new medication kit will need to be assigned through IRT. 
The amount of study  drug dispensed at the time of dose reduction and dose re -escalation is 
dependent upon the amount of time between the dose adjustment visit and the next planned 
study  visit. I RT will assign onl y the number of study medication kits needed until the next 
planned patient visit.
Sildenafil and matching placebo 4.1.4.2
Treatment with sildenafil (or matching placebo) will consist of 1 capsule three times 
daily  (tid). 
The first administration of sildenafil (or matching placebo) will b e taken in the clinic 
at visit 2 . 
Sildenafil capsules should be taken approximately 6 to 8 hours apart.
Itis recommended that nintedanib and sildenafil are administered together at the same 
time in the morning and evening at the end of a meal , with the third sildenafil dose 
administered at the midpoint. 
If a dose of sildenafil is missed, administration should resume at the next scheduled 
time at the recommended dose.  Double doses should not be taken to make up for 
forgotten capsules . 
No dose adjustments are allowed for sildenafil within this study .
4.1.5 Blinding and procedures for unblinding
Blinding 4.1.5.1
Patients, i nvestigator s and every one involved in trial conduct or analy sisor with an y other
interest in this double -blind trial(apart from the DMC) will remain blinded with regard to the 
randomized treatment assignments until after database lock.
The randomization code will be kept secret by  Clinical Trial Support up to database lock.
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 32of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
The DMC may  review unblinded data upon request, and only  under conditions that ensure 
that patients, investigators and everyone involved in trial conduct or analy sis or with any  
other interest in this double- blind trial will remain blinded.
Unblinding and breaking the code 4.1.5.2
Emergency  unblinding will be available to the Investigator / Pharmacist / investigational drug 
storage manager via IRT. It must only  be used in an emergency  situation when the identity  of 
the trial drug must be known to the Investigator in order to provide appropriate medical 
treatment or otherwise assure safety  of trial participants . The reason for unblinding must be 
documented in the source documents and/or appropriate CRF page along with the date and 
the initials of the person who broke the code.
Due to the requirements to report Suspected Unexpected Serious Adverse Reactions
(SUSARs ), it may  be necessary  for a representative from Boehringer Ingelheim’s
Pharmacovigilance group to access the randomisation code for individual patients during trial
conduct. The access to the code will onl y be given to authorised Pharmacovigilance
represe ntatives and not be shared further.
For Japan only :In this blinded trial, an emergency code break will be available to the 
Investigator / the sub -Investigators via the IRT s ystem. This code break may  only  be accessed 
in emergency situations when the ident ity of the trial drug must be known to the I nvestigator 
/the sub- Investigators in order to provide appropriate medical treatment or if required to 
assure the safet yof trial participants. Each site receives a manual from the IRT provider that 
contains instructions on how to unblind the treatment of a patient via the IRT (via 24 -hour 
Emergency helpline). If the code break for a patient is accessed, the s ponsor must be 
informed immediately . The reason for accessing the code break, together with the date, must
bedocumented on the appropriate eCRF page. In case third party  needs to break the code,
however, when the Investigator cannot be reached, the code can be opened by  calling
emergency  code manager.
4.1.6 Packaging, labelling , and re -suppl y
Nintedanib will be packaged in blisters (containing either nintedanib 100 mg or n intedanib 
150mg). Each blister will contain 10 capsules. Seven blisters will be packaged into one 
child- resistant tamper -evident wallet (i.e. 70 capsules/wallet). 
Sildenafil / matching placebo will be packaged in blisters. Each blister will contain 15
capsules. Seven blisters will be packaged into one child- resistant tamper -evident wallet (i.e. 
105 capsules/wallet). 
For details of packaging and the description of the label, refer to the ISF.
Re-supplies of study  medication are planned due to the long duration of the study . The 
medication for re -suppl y will be packaged in an identical manner as the medication for initial 
supply .
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 33of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
4.1.7 Storage conditions
Drug supplies willbe kept in their original pa ckaging and in a secure limited access storage 
area according to the recommended storage conditions on the medication label. A
temperature log must be maintained for documentation.
If the storage conditions are found to be outside the specified range, the local clinical monitor 
(as provided in the list of contacts) must be contacted immediately .
4.1.8 Drug accountability
The Investigator and/or Pharmacist and/or investigational drug storage manager will receive 
the investigational drugs delivered b y the sponsor when the following requirements are 
fulfilled:
Approval of the trial protocol by  the IRB / ethics committee, 
Availability  of a signed and dated clinical trial contract between the s ponsor and the 
head of the investigational site ,
Approval/notification of the regulatory  authority , e.g. competent authorit y,
Availability  of the curriculum vitae of the principal Investigator ,
Availability  of a signed and dated clinical trial protocol
If applicable, availability of the proof of a medical license for the principal 
Investigator
In the USA, a vailability  of Form 1572
The Investigator and/or Pharmacist and/or investigational drug storage manager must 
maintain records of the product’s delivery  to the trial site, the inventory  at the site, the use by  
each patient, and the return to the s ponsor or alternative disposal of unused products. 
These records will include dates, quantities, batch /serial numbers, expiry  (‘use -by’) dates, 
and the unique code numbers assigned to the investigational product and trial patients. The 
Investigator / Pharmacist / investigational drug storage manager will maintain records that 
document adequately that the patients were provided the doses specified b y the CTP and 
reconcile all investigational products received from the 
sponsor . At the time of return to the 
sponsor or appointed CRO, the Investigator / Pharmacist / investigational drug storage 
manager must verify  that all unused or partiall y used drug supplies have been returned b y the 
clinical trial patient and that no re maining supplies are in the Investigator ’s possession.
CONCOMITANT THERAPY, RESTRICTIONS, AND RE SCUE 4.2
TREATMENT
4.2.1 Rescue medication, emergency  procedures, and additional treatment
Rescue medications to reverse the action of nintedanib or sildenafil are not available.
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 34of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Recommendations for managing AEs (exceptions include diarrho ea and liver 4.2.1.1
enzy meelevations)
If a patient experiences adverse events considered related to the trial medication ,
symptomatic treatment should be initiated (e.g. anti -emeti c treatment such as 
dimenhy drina te,if appropriate). 
Patients experiencing adverse events considered related to nintedanib may  require 
drug interruption (up to a maximum of 4 weeks) or reduction of dose (at the discretion 
of the investigator) to allow for resolution of sy mptoms. 
After resolution of AE, nintedanib may  be reintroduced and /orre-escalated to the 
higher dose (at the discretion of the investigator):
a.If dose has been reduced, consider re -escalation to 150 mg bid  
b.If treatment was temp orarily  interrupted, resume treatment at the full dose 
(150 mg bid), or at the reduced dose (100 mg bid), which subsequentl y ma y be 
re-escalated to the full dose (150 mg bid).
Patients experiencing adverse events considered related to sildenafil may  requir e drug 
interruption (up to a maximum of 4 weeks) to allow for resolution of sy mptoms. No 
dose adjustments are allowed for sildenafil within this study . In the event of an 
erection that persists longer than 4 hours, the patient should seek immediate medical
assistance.
For adverse events not related to the trial medications , treatment interruption s for a 
maximum of 4 weeks are allowed. Nintedanib and sildenafil should then be re sumed 
at the same dose taken prior to interruption.  
In the occurrence of acute IPF exacerbation s all treatment options considered 
adequate b y the investigator are allowed.  
Recommendations for managing diarrh oea 4.2.1.2
In general, diarrho ea should be managed as early  as possible after onset of first sy mptoms 
with standard antidiarrheal sy mptomatic treatment, e.g. lop eramide.
If diarrh oea persists despite optimal sy mptomatic treatment, treatment interruption (for a 
maximum of 4 weeks) and dose reduction of nintedanib should be considered based on the 
recommendations described in Table 4.2.1.2: 1 .
If diarrh oea is not manageable after dose reduction and/or nintedanib interruption ,
interruption of sildenafil should also be considered.
Boehringer Ingelheim 18 Aug 2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 35of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Table 4.2.1.2: 1 Recommendations for managing diarrh oea
CTCAE 
GradeDescription Symptomatic Treatment Action with Nintedanib
1Increase of <4 
stools per day  
over baselineInitiate anti- diarrheal 
medicines at first signs of 
symptoms (e.g., 4 mg 
loperamide followed b y 2 mg 
after each loose stool or every  
2-4 hours to a maxi mum of 
16 mg/day1) until bowel 
movements cease for 12 
hoursContinue same nintedanib dose
2Increase of 4 -6 
stools per day  
over baselineInitiate/continue anti -
diarrheal medicines;
If diarrh oeagrade 2 persists 
for ≥48-72 hours assess for 
dehy dration and electrol yte 
imbalance; 
In addition, consider i.v.
fluids and electrol yte 
replacement as clinicall y 
indicated.If diarrh oeagrade 2 persists for 
≥48-72 hours despite optimal 
symptomatic care: 
Interrupt nintedanib until 
recovery2
Reduce dose to 100 mg bid 
after recovery  
Re-escalate to 150 mg bid if 
deemed clinically appropriate
3
Or
4Increase of ≥ 7 
stools per day  
over baseline; 
incontinence; 
Or
Life threatening 
consequencesFollow recommendations 
above.
In addition, consider stool 
work -up to exclude infectious 
colitis; aggressive i.v.fluid 
replacement ≥24 hours, 
hospitalisation as clinically  
indicated; consider referral to 
a GI specialist to rule out 
potential differential 
diagnos es.Interrupt nintedanib until 
recovery2
Reduce dose to 100 mg bid 
after recovery
Consider re -escalation to 150 
mg bid if deemed clinically  
appropriate
In case of recurrence of 
diarrh oeagrades 3 or 4 despite 
optimal sy mptomatic treatment 
and dose reduction, treatment 
with nintedanib should be 
permanentl y discontinued.
1  Refer to national prescribing information
2Treatment interruptions are allowed up to a maximum of 4 weeks.
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 36of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Recommendations for managing liver enz yme elevations 4.2.1.3
For a detailed guidance on how to manage l iver enzy me elevations, please refer to table 4.2.1.3 : 1
Table 4.2.1.3: 1 Recommendations for managing liver enz yme elevations
AST /ALT ≥3 but <5 x ULN AST /ALT ≥5 but <8 x ULNSigns of hepatic 
injury3
Reduce nintedanib to 100 mg bid or interrupt2(at the 
discretion of the investigator) 
Lab tests1at 48/72 hours, at 1 week and at 2 w eeksInterrupt2nintedanib
Lab tests1at 48/72 hours, at 1 week and at 2 w eeksPerm anently 
discontinue all 
study drugs
If AST /ALT < 3 x ULN
within 2 weeksIf AST /ALT ≥3 ULN        
at 2 weeksIf AST /ALT < 3 x ULN
within 2 weeksIf AST /ALT ≥3 ULN        
at 2 weeks
Re-escalate nintedanib to 
150 mg bid if reduced ; 
restart at 100 mg bid if 
interrupted
Lab tests1at weeks 2 and 4Interrupt2both drugs
Lab tests1at weeks 1 and 2Reintroduce nintedanib at 
100 mg bid
Lab tests1at weeks 1, 2 
and4Interrupt2sildenafil
Lab tests1at weeks 1 and 2
If AST / ALT ≥ 3 x ULN
permanently discontinue 
nintedanibIf AST / ALT < 3 x ULN
reintroduce drugs in a 
stepwise approach; lab tests1
every week as needed
If AST / ALT ≥ 3 x ULN
permanently discontinue all 
study drugsIf AST / ALT ≥ 3 x ULN
permanently discontinue 
nintedanibIf AST / ALT < 3 x ULN
reintroduce drugs in a 
stepwise approach; lab tests1
every week as needed
If AST / ALT ≥ 3 x ULN
permanently discontinue all 
study drugs
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 37of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
1Laboratory tests include AL T, AST, total bilirubin, eosinophils, I NR
2Treatment interruptions are allowed up to a maximum of 4 weeks.
3Signs of hepatic injury are defined as:
ALT and/or AST ≥ 8 fold ULN
ALT and/or AST ≥ 3 fold ULN and total bilirubin ≥2 fold ULN
ALT and/or AST ≥ 3 fold ULN and unexplained INR > 1.5
ALT and/or AST ≥ 3 fold ULN and unexplained eosinophilia (> 5%)
ALT and/or AST ≥ 3 fold ULN and appearance of fatigue, nausea, vomiting, right 
upper abdominal quadrant pain or tenderness, fev er and/or rash.
For potential drug induced liver injury  (DILI) follow up requirements please see section 
5.3.6.1 .
4.2.2 Restrictions
Restrictions regarding concomitant treatment 4.2.2.1
Concomitant medications (or therap y) to provide adequate care may  be given as clinicall y 
necessary . If restricted concomitant therapy  is necessary ,treatment with study  medication 
should be permanentl y discontinued (except in case of acute IPF exacerbations – refer to 
section 4.2.1.1). 
Table 4.2.2.1:1 Permitted and Restricted Concomitant therapy  
Prior to 
randomisationDuring 
treatment 
periodAfter Visit 7 
(Follow -up 
Period)After early
EOT9
NintedanibPermitted (150 mg 
bid dose only)Study 
medicationPermitted Not permitted
SildenafilNot permitted in 
the 4 weeks prior 
to visit 2 1Study 
medicationPermitted Not permitted
Pirfenidone , N-
acetylcysteine, 
Azathioprine, 
Cyclophosphamide,  
CyclosporineNot permitted in 
the 4 weeks prior 
to visit 2 1Not permitted Not permitted Permitted
Prednisone and  other 
oral corticosteroid2Not permitted in 
the 4 weeks prior 
to visit 2 1Not permitted Not permitted Permitted
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 38of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Table 4.2.2.1:1 (continued) Permitted and Restricted Concomitant therapy  
Investigational 
MedicationNot permitted in 
the 4 weeks prior 
to visit 2 1Not permittedNot 
permitted10 Not permitted
NitratesNot permitted in 
the 4 weeks prior 
to visit 2 1Not permitted Not permitted Permitted
Prostaglandins3, 
endothelin -1 
antagonists4or 
phosphodiesterase 
inhibitor s5or a 
stimulator of 
guanylatcyclase 6Not permitted in 
the 4 weeks prior 
to visit 2 1Not permitted Not permitted Not permitted
Potent CYP3A4 
inhibitors such as 
ketoconazole, 
itraconazole and 
ritonavirNot permitted in 
the 4 weeks prior 
to visit 2 1Not permitted Not permitted Permitted
L-arginine, grapefruit 
juice or St John’s wortNot permitted in 
the 4 weeks prior 
to visit 2 1Not permitted Not permitted Permitted
Anticoagulation at full 
dose7,antiplatelet 
therapy at high dose 8,
fibrinolysisPermitted Not permitted Not permitted Permitted
1.Washout should not occur until after patient has signed informed consent
2.Prednisone >15 mg daily or >30 mg every  2 day s OR equivalent dose of other oral 
corticosteroids .
3.e.g., epoprostenol, treprostinil
4.e.g., bosentan, sitaxsentan, ambrisentan
5.e.g., sildenafil, tadalafil, vardenafil
6.e.g., riociguat
7.Anticoagulation at full dose (vitamin K antagonists, direct thrombin inhibitors , heparin, 
hirudin, etc.). Exceptions: prophy lactic low dose heparin or heparin flush as needed for 
maintenance of an indwelling intravenous device (e.g. enoxaparin 4000 IU s.c .per day )
8.Antiplatelet therap y at high dose. Exceptions: prophy lactic use of antiplatelet therap y 
(e.g. ac etylsalicy lic acid up to 325 mg/day  and/ or clopidogrel at 75 mg/day and/or 
equivalent doses of other antiplatelet therap y) is allowed 
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 39of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
9.For patients who withdrew allstudy  medication s before the planned EOT date and decide 
to attend all remaining study  planned visits.
10.Nintedanib as investigational product is allowed during the follow -up period in case the 
patient transitions to an extension trial or compassionate use program.
Wash -out periods for concomitant therap y which might influence the spirometry results are 
described in section 5.2.2.
Restrictions on diet and life sty le 4.2.2.2
There are no restrictions on diet and life sty le.
Restrictions regarding women of childbearing potential 4.2.2.3
The anti -angiogenic properties of nintedanib indicate a high potential for teratogenicit y 
and/or embry otoxicity , including fetotoxicity /lethality . In women of childbearing potential 
receiving nintedanib , contraceptive measu res must be employ ed 28 day s before treatment 
initiation, during the trial and for a period of 3 months after last drug intake .
TREATMENT COMPLIANCE 4.3
Patients are requested to bring all remaining trial medication including empty  package 
material with them when attending visits.
Based on capsule counts, treatment compliance will be calculated as the number of capsules 
taken, divided by the number of capsules which should have been taken according to the 
scheduled period, multiplied by  100. A compliance worksheet will be provided in the I SF. 
Treatment compliance (%) =Number of capsule actually  taken 100
     Number of capsules which should have been 
taken
If the number of doses taken is not between 80 -120% (inclusive) without identified cause like 
AE or consent withdrawal, site staff will explain to the patient the importance of treatment 
compliance. 
In addition, the compliance calculation should be cross- checked with the patient diary  and 
discrepancies docume nted accordingl y (section 5.3.5 ).
Compliance will be verified by  the on -site monitor authorized by  the sponsor.
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 40of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
5. VARIABLES AND THEIR ASSESSMENT 
TRIAL ENDPOINTS 5.1
5.1.1 Primary  Endpoint
The primary  endpoint is the c hange from baseline in St G eorge’s Respiratory Questionnaire 
(SGRQ )total score at week 12.
5.1.2 Secondary  Endpoints
Change from baseline in dy spnea using theUniversity  of California San Diego 
Shortness of Breath Questionnaire (UCSD SOBQ )atweek 12;
Change from baseline in SGRQ total score at week 24 ;
Change from baseline in dy spnea using UCSD SOBQ at week 24;
Percentage of patients with on -treatment Serious Adverse Events ( SAE )from baseline 
to week 24.

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 41of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
ASSESSMENT OF EFFICA CY 5.2
5.2.1 Patient Reported Outcomes 
Three different PRO questionnaires will be used:
St George’s Respiratory  Questionnaire (SGRQ – See Appendix 10.3)
The UCSD Shortness of Breath Questionnair e (UCSD -SOBQ –See Appendix 10.4 )
EuroQoL -5D  (EQ -5D – See Appendix 10.5)
ThePRO questionnaire swill be assessed at timepoints as indicated in the flow chart .It 
should be completed at the start of each applicable visit, prior to performing any  other trial 
procedures and in the following order: SGRQ, UCSD -SOBQ, EQ -5D.
5.2.2 Forced Vital Capacity , Carbon Monoxide Diffusion Capacity , Alveolar Volume, 
Oxygen Saturation and Arterialised Blood Gases
FVC will be assessed using identical spirometry  devices which will be supplied to all 
participating sites at trial initiation and spirometry  performance will be centrally  reviewed. 
Spirometers and usage of spirometers must meet ATS/ERS criteria [ P05-12782 ], including 
daily  calibration of the spirometer, and regular calibration of the calibration pump (according 
to the instructions provided in the I SF).Spirometry  will be conducted while the patient is in 
a seated position. The test will be done in triplicate and the best result selected according to 
the guidelines. Spirometry results captured b y spirometers provided b y the sponsor will be 
electronically  transmitted and confirmed b y central reading. The best of three efforts will be 

Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 42of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
defined as the highest FVC, obtained on any  of the three blows meeting the ATS/ERS 
criteria , preferably with a maximum of five manoeuvres .
The site will use its own equipment to assess carbon monoxide diffusion capacit y (DLCO) 
and alveolar volume (V A) during the single breath diffusion test
and conduct all 
measurements with the same equipment (e.g. if several devices would be available at the 
site). Single -breath diffusion test will be carried out according to the ATS / ERS guideline s
[R06-2002] . Before beginning t he test, the manoeuvres should be demonstrated and the 
subject carefull y instructed. The mean value between at least two acceptable tests should be 
reported. Please refer to Appendix 10.6 for additional information.
For each patie nt, pulmonary  function testing and single -breath diffusion test will alway s start 
at approximately  the same time of day .The DL CO/VA assessment should alway s be 
performed after the FVC assessment.
On day s of clinic visits, patients must refrain from strenu ous activity  at least 12 hours prior to 
pulmonary  function testing. 
Smoking should be discouraged throughout the study  day (clinic visit) and will not be 
permitted in the 30 -minute period prior to spirometry . Patients should also avoid cold 
temperatures, environmental smoke, dust, or areas with strong odours (e.g., perfumes).
Washout of bronchodilators therapies (betamimetic drugs, anticholinergic drugs) has to be 
observed before spirometry  (24 hours for long acting and 8 hours for short acting 
bronchodilators ). 
Oxygen saturation ( SpO 2) will be measured at rest by  standard pulse oximetry  (unaffected 
skin of earlobe or fingertip ). Arterialised blood gases (PaO 2and PaCO 2) will be measured in 
selected sites experienced in earlobe capillary  blood gas sampling . Valueswill be entered in
theeCRF.
5.2.3 Acute IPF e xacerbations
Acute IPF exacerbations will be collected as adverse events .
Acute IPF exacerbation is defined as an acute, clinically  significant, respiratory  deterioration 
characterized b y evidence of new widespread alveolar abnormalit y [P16-06899
]. 
Extra -parench ymal causes (e.g. pneumothorax, pleural effusion, pulmonary  embolism) 
should be excluded and the following 3 d iagnostic criteria need to be met:
Acute worsening or development of dy spnea t ypically of less than one month 
duration;
Computed tomograph y with new bilateral ground -glass opacity  and/or consolidation 
super imposed on a background pattern consistent with usual interstitial pneumonia 
pattern;
Deterioration not fully  explained by  cardiac failure or fluid overload.
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 43of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Events that are clinically  considered to meet the definition of acute exacerbation of I PF but 
failto meet the three diagnostic criteria due to missing computed tomography  data will be 
termed “suspected acute exacerbations” b y the Adjudication Committee.
ASSESSMENT OF S AFETY 5.3
5.3.1 Physical examination
Physical examination includes assessment of heart, lung, abdomen and measurement of 
weight. Height will also be measured at visit 1. A bnormal findings at the time of screening 
will be recorded as baseline conditions on the appropriate eCRF page. New abnormal 
findings or worsening of baseline conditions detected at the subsequent ph ysical 
examinations will be recorded as adverse events on the appropriate eCRF page.
5.3.2 Vital Signs
Vital signs, including measurements of s ystolic and diastolic blood pressure and pulse rate,
will be measured with the patient seated after having rested for at least 5 minutes .
5.3.3 S afety  laboratory  parameters
The laboratory  tests will include:
Haematology :complete blood count including platelet count and automated differential.
Chemistry : sodium, potassium, creatinine, aspartate aminotransferase ( AST ), alanine 
transaminase ( ALT), g amma -glutam yl transferase   
(GGT), total protein, a lkaline 
phosphatase (ALP) ,total bilirubin, lactate dehy drogenase (LDH), creatine kinase , brain 
natriuretic peptide (BNP) and thy roid stimulating hormone (TSH).
Coagulation : International normalized ratio (INR) and partial thromboplastin time (PTT).
Urine : pregnancy  testing (forall women of childbearing potential ).
If laboratory  values indicate toxicity , adequate and more frequent blood sampling will be 
performed at the discretion of the investigator.
Laboratory  anal ysis will be done using central laborat ory services. Venous whole blood will 
be collected in appropriate sy ringes provided by  the sponsor through the assigned central 
laboratory . Details regarding centrifuge, processing, storage and shipment of samples will be 
determined b y the central laborato ry in accordance with the sponsor. The investigators will be 
informed and instructed by  the central laboratory  and detailed documentation will be included 
in the I SF.
In case of liver enz yme elevation s, close monitoring must be ensured b y the investigator
(section 4.2.1. 3).
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 44of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
5.3.4 Electrocardiogram
ECGs are to be conducted with site equipment as specified in the flow chart . Changes should 
be examined , compared to the previous test , and assessed for clinical relevance. Clinicall y 
relevant findings at visit 1 will be recorded as baseline conditions, new abnormal findings 
thereafter will be recorded as adverse events.
5.3.5 O ther safety  parameters
A patient diary  will be used by  all patien ts in this trial to record s ymptoms and numb er of 
capsules taken per day . The diary  will be used to prompt patient recollection during AE and 
medication compliance discussions at clinic visits. I nstructions for use of the diary  will be 
provided in the I SF.
5.3.6 Assessment of adverse events
Definitions of AEs 5.3.6.1
Adverse event
An adverse event (AE) is defined as a ny untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal product and which does not necessarily  have 
to have a causal relationship with this treatment.
An AE can therefore be any  unfavourable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
product, whether or not considered related to the medicinal product.
Adverse reaction
An adverse reaction is defined as a response to a medicinal product which is noxious and 
unintended.  Response in this context means that a causal relationship between medicinal 
product and an adverse eve nt is at least a reasonable possibility .  Adverse reactions may  arise 
from use of the product within or outside the terms of the marketing authorisation or from 
occupational exposure.  Conditions of use outside the marketing authorization include off -
label use, overdose, misuse, abuse and medication errors. 
Serious adverse event
A serious adverse event (SAE) is defined as any AE which:
results in death,
is life -threatening,
requires inpatient hospitalisation or prolongation of existing hospitalisation,
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 45of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
results in persistent or significant disability  or incapacity ,
is a congenital anomal y/birth defect, or
is to be deemed serious for an y other reason if it is an important medical event when 
based upon appropriate medical judgment which may  jeopardize the patient and may  
require medical or surgical intervention to prevent one of the other outcomes listed in 
the above definitions. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalisation or development of dependency  or 
abuse. An y suspected transmission via a medicinal product of an infectious agent is 
considered a serious adverse reaction.
Life-threatening in this context refers to an event in which the patient was at risk of death at 
the time of the event; it does not refer to an event that hy pothetically  might have caused death 
if more severe.
For Japan only :The following events will be handled as “deemed serious for any  other 
reason”. An AE which possibly  leads to disability will be reported as a SAE.
Other significant adverse event (according to ICH E3)
An “o ther significant adverse event” is defined as any  non- serious adverse event which 
represents a marked haematological or other laboratory  abnormality ;
led to an intervention, including withdrawal of drug treatment, dose reduction or 
significant additional concomitant therap y.
AEs considered “Always Serious”
Cancers of new histology and exacerbations of existing cancer must be reported as a serious 
event regardless of the duration between discontinuation of the drug and the occurrence of the 
cancer.
In accordance with the European Medicines Agency initiative on Important Medical Events, 
Boehringer Ingelheim has set up a list of further AEs, which by  their nature, can alway s be 
considered to be “serious” even though they  may  not have met the criteria of an SAE as given 
above.
The latest list of “Alway s Serious AEs” can be found in the RDC system. These events 
should alway s be repo rted as SAEs as described in section 5.3.7 .
Adverse events of special interest (AESIs)
The term AESI relates to any  specific AE that has been identified at the project level as being 
of particular concern for prospective safet y monitoring and safet y assessment within this trial, 
e.g. the potential for AEs based on knowledge from other compou nds in the same class. AESI 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 46of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
need to be reported to the sponsor’s Pharmacovigilance Department within the same 
timeframe that applies to SAE s, see section 5.3.7 .
The following are considered AESIs:
Adverse events relating to gast rointestinal perforation
and 
Hepatic injury
In this stud y protocol, signs of hepatic injury  are defined as:
ALT and/or AST ≥ 8 fold ULN
ALTand /or AST ≥ 3 fold ULN and total bilirubin ≥ 2 fold ULN *
ALT and /or AST ≥ 3 fold ULN and unexplained INR > 1,5 *
ALTand /or AST ≥ 3 fold ULN and unexplained eosinophilia (>5%) *
ALT and /or AST ≥ 3 fold ULN and appearance of fatigue, nausea, vomiting, right 
upper abdominal quadrant pain or tenderness, fever and/or rash
* in the same blood draw sample.
These lab find ings constitute a hepatic injury  alert and the patients showing these lab 
abnormalities need to be followed up according to the “DILI checklist” provided in the I SF.
In case of clinical s ymptoms of hepatic injury  (icterus, unexplained encephalopathy , 
unexp lained coagulopathy, right upper quadrant abdominal pain, etc.) without lab results 
(ALT, AST, total bilirubin) available, the investigator should make sure these parameters are 
analysed, if necessary  in an unscheduled blood test. Should the results meet t he criteria of 
hepatic injury  alert, the procedures described in the DILI checklist should be followed .
Intensity of AEs
The intensity  of the AE should be judged based on the following:
Mild: Awareness of sign(s) or sy mptom(s) that is/are easily  tolerated
Moderate: Enough discomfort to cause interference with usual activity
Severe: Incapacitating or causing inability  to work or to perform usual activities
The intensity  of diarrhoea adverse ev ents should in addition be classified and recorded in the 
(e)CRF according to the Common Terminology  Criteria for Adverse Events (CTCAE )
version 4 [ R10-4848
].
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 47of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Table 5.3.6: 1 CTCAE Categorization for diarrhoea
CTCAE Grade
1 Increase of <4 stools per day over baseline
2 Increase of 4 to 6 stools per day over baseline
3 Increase of ≥7 stools per day over baseline; incontinence
4 Life threatening consequences
5 Death
Causal relationship of AEs
The definition of an adverse reaction implies at least a reasonable possibility of a causal 
relationship between a suspected medicinal product and an adverse event. An adverse 
reaction, in contrast to an adverse event, is characterised b y the fact that a causal relationship 
between a medicinal product an d an occurrence is suspected.
Medical judgment should be used to determine the relationship, considering all relevant 
factors, including pattern of reaction, temporal relationship, de -challenge or re -challenge, 
confounding factors such as concomitant medic ation, concomitant diseases and relevant 
history .
Arguments that may  suggest that there is a reasonable possibility  of a causal relationship 
could be:
The event is consistent with the known pharmacology  of the drug
The event is known to be caused b y or att ributed to the drug class.
A plausible time to onset of the event relative to the time of drug exposure.
Evidence that the event is reproducible when the drug is re- introduced
No medicall y sound alternative aetiologies that could explain the event (e.g. 
preexisting or concomitant diseases, or co -medications).
The event is t ypicall y drug -related and infrequent in the general population not
exposed to drugs (e.g. Stevens- Johnson sy ndrome).
An indication of dose -response (i.e. greater effect size if the dose is increased, smaller 
effect size if dose is diminished).
Arguments that may  suggest that there is no reasonable possibility  of a causal relationship
could be:
No plausible time to onset of the event relative to the time of drug exposure is evident
(e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days / weeks
of drug administration; an allergic reaction weeks after discontinuation of the drug
concerned)
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 48of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Continuation of the event despite the withdrawal of the medication, taking into
account the pharmacological properties of the compound (e.g. after 5 half -lives). Of 
note, this criterion may  not be applicable to events whose time course is prolonged
despite removing the original trigger.
Additional arguments amongst those stated before , like alternative explanation (e.g.
situations where other drugs or underl ying diseases appear to provide a more likely
explanation for the observed event than the drug concerned).
Disappearance of the event even though the study  drug treatment continues or remains 
unchanged.
For Japan only : The reason for the decision on causal relationship for unlisted AEs needs to 
be provided in the e CRF.
5.3.7 Adverse event collection and reporting
AE Collection
The investigator shall maintain and keep detailed records of all AEs in the patient files.
The following must be collected and documented on the appropriate eCRF by  the 
Investigator:
From signing the informed consent onwards through the Residual Effect Period (REP ), 
until individual patient’s end of trial: all AEs ( serious and non- serious) and all AESI s.
However, if an individual patient discontinues trial medication prematurel y but stay s 
in the trial (i.e. if further visits incl. telephone visits, or vital status assessments are 
planned) from then on and until the i ndividual patient’s end of the trial the 
Investigator must report related SAEs and related AESI s.
After the individual patient’s end of trial: 
the investigator does not need to activel y monitor the patient for AEs but should only
report relevant SAEs and relevant AESIs of which the investigator may  become aware 
of.
Figure 5.3. 7:1AE Collection

Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 49of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
The Residual Effect Period ( REP)is defined as 28days after the last trial medication 
administration. All AEs which occurred through the treatment phase and throughout the REP 
will be considered as on treatment please see section 7.3.4 .Events which occurred after the 
REP will be considered as post treatment events.
AE reporting to spon sor and timelines
The Investigator must report SAEs, AESI s, and non -serious AEs which are relevant for the 
reported SAE or AESI, on the BI SAE form via fax immediately (within 24 hours ) to the 
sponsor’s unique entry  point (country  specific contact details will be provided in the I SF).
The same timeline applies if follow-up information becomes available. In specific occasions 
the Investigator could inform the sponsor upfront via telephone. This does not replace the 
requirement to complete and fax the BI SAE form.
With receipt of an y further information to these events, a follow -up SAE form has to be 
provided. For follow -up information the same rules and timeline apply  as for initial 
information.
For Japan only :All SAEs must be reported immediately  to the he ad of the trial site. With 
receipt of an y further information to these events, a follow -up SAE form has to be provided. 
For follow -up information the same rules and timeline apply as for initial information.
Information required
For each AE, the Investiga tor should provide the information requested on the appropriate 
eCRF pages and the BI SAE form . The Investigator should determine the causal relationship 
to the trial medication .
The following should also be recorded as an (S)AE in the eCRF and SAE form (i f 
applicable):
Worsening of the underly ing disease or of other pre -existing conditions
Changes in vital signs, ECG, phy sical examination and laboratory  test results, if they  
are judged clinically  relevant by  the Investigator.
If such abnormalities already  
pre-exist prior trial inclusion they  will be considered as baseline 
conditions.
All (S)AEs, including those persisting after individual patient’s end of trial must be followed 
up until they  have resolved, have been sufficiently  characterized, or no further information 
can be obtained.
Pregnancy
In rare cases pregnancy  may  occur in a clinical trial. Once a patient has been enrolled into
this clinical trial and has taken trial medication, the Investigator must report immediately
(within 24 hours) a potential drug exposure during pregnancy  (DEDP) to the sponsor’s
unique entry point (country -specific contact details will be provided in the ISF). The
Pregnancy  Monitoring Form for Clinical Trials (Part A) should be used.
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 50of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
The outcome of the pregnancy  associated wi th the drug exposure during pregnancy  must be 
followed up and reported to the s ponsor’s unique entry  point on the Pregnancy  Monitoring 
Form for Clinical Trials (Part B). 
The I SF will contain the Pregnancy  Monitoring Form for Clinical Trials (Part A and B) .
As pregnancy  itself is not to be reported as an AE, in the absence of an accompany ing SAE, 
and/or AESI, only the Pregnancy Monitoring Form for Clinical Trials and not the SAE form 
is to be completed. If there is an SAE and/or AESI associated with the pre gnancy , anSAE 
form must be completed in addition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 51of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 52of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 53of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
OTHER ASSESSMENTS 5.6
Not applicable.
APPROPRIATENESS OF M EASUREMENTS 5.7
All measurements conducted in the trial are using standard me thods. 

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 54of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
6. INVESTIGATIONAL PLAN
VISIT SCHEDULE 6.1
Informed consent of all study  patients will be obtained in compliance with ICH and GCP 
guidelines and the principles stipulated in the Declaration of Helsinki prior to any  study  
related procedures, including any washout of restricted medications (refer to table 4.2.2.1:1 ). 
The study  will consist of a screening period up to 28 day s, a randomised treatment period of 
24 weeks and a follow up period lasting a minimum of four weeks (28 day s). 
All patients are to adhere to the visit schedule as outlined in the flow chart . Some flexibility  is 
allowed in scheduling the visits according to the visit time windows as specified. The trial 
medication kits contain sufficient medication to allow for these time windows. All deviations 
from the planned visit schedule will be documented.  If an y visit is to be re -scheduled, 
subsequent visits should follow the orig inal visit date s chedule (calculated from visit 2 ). No 
protocol waivers will be given (e.g. sponsor will not grant permission to include a known 
ineligible patient).
DETAILS OF TRIAL PRO CEDURES AT SELECTED VISITS 6.2
6.2.1 Screening and run -in period(s)
Screening P eriod
No study  related procedures will be performed until the patient has signed informed consent. 
The study  will be explained to patients and those who meet entry  criteria ( section 3.3 ) will be 
invited to participate.  
Please refer to the flow chart for complete procedures at visit 1. 
An echocardiogram will be performed with site equipment at visit 1 to evaluate cardiac 
function and assess exclusion criteria 10, 11 and 1 2 (section 3.3.3 ). In addition, t his test will 
be used for the stratification of patients during randomization (as described in section 7.6 ).
The following questions will be captured in the eCRF based on the investigator’s judgement :
Presence of right ventricular sy stolic dy sfunction (y es/no)
Presence of right ventricular hy pertrophy  (yes/no)
Presence of right ventricular dilatation (yes/no)
Presence of paradoxical septum motion (y es/no)
Presence of right atrium enlargement (y es/no)
Clinically  relevant findings will be recorded as baseline conditions.
Patients who have a laboratory  test, blood pressure or lung function test value outside the 
range specified b y the exclusion criteria and thought to be a measurement error or the result 
of a temporary  and r eversible medical condition may have the test repeated once to determine 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 55of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
eligibility ; however, the result must be available prior to v isit 2. The period between visit 1 
and visit 2 should last a maximum of 28 day s.If visit 2 could not be performed within this 
timeframe the patient willbe considered as screen failed. 
All patients who have signed consent must be entered in the enrolment log and documented 
in the eCRF. Patients found to be ineligible at or prior to visit 2 and do not initiate treatment 
willbe considered a screen failure.
6.2.2 Treatment period(s)
If the patient has been determined eligible b y the investigator to enter the trial (refer to
section 3.3), the investigator will assign medication number s to the patient through the IRT 
system at visit 2. First dose of trial drugs will be administered at visit 2 in the clinic (day  1).
Additional clinic vi sits will be scheduled after 4, 8 , 12, 18 and 24 weeks of treatment (visits 
3-7). For detailed description of the trial procedu res at each visit and dispensing schedule, 
please refer to the flowchart.
Dose Adjustment Visit
The dose of nintedanib can be reduced and increased as described insection 4.2.1 . In this 
case, the patient will be required to return to the clinic for anunscheduled visit where new 
medication will be assigned via the IRT s ystem. Please refer to the flow chart for complete 
procedures in this visit.
6.2.3 Follow Up Period and Trial Comple tion
A follow -up (FU P) visit should be planned for 28 day s after last trial drug administration .For 
detailed description of the trial procedures at the FUP visit, please refer to the flow chart.
Trial completion
The trial completion eCRF page has to be filled -in when the patient has terminated the trial. 
The end of the trial is:
At the end of the follow -up visit for patients who have completed the trial on 
treatment as planned ;
After the early end of treatment (EOT) and follow -up visit s, if a patient did not agreed
to come to the remaining planned study  visits;
At the end of visit 7 for patients who discontinued drug earl y but agreed to come to 
the remaining planned study  visits.
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 56of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Patients who prematurel y discontinued trial medication
Patients who prematurel y discontinue all study  drugs (refer to section 3.3.4 ) before the 
planned end of treatment at visit 7, should come to the clinic as soon as possible after last 
drug intake for an earl y EOT visit. Reason for discontinuation must be documented in the 
eCRF. For detailed description of the trial procedures at this visit, please refer to the flow
chart . 
In addition patients will be invited to attend all planned visits despite not being unde r 
treatment an ymore and perform all stud y procedures except the laboratory tests (optional), 
biomarker sampling, pharmacokinetic sampling and the ECG. If patients don’t accept to 
attend all remaining study visits, they  will be contacted for vital status co llection at week 24.
The need for coming to future visit s in case of premature discontinuation of trial medication 
will be explained to patients prior to their participation in the trial. 
Vital status information
In case of earl y discontinuation of all study  drugs , if the patient does not agree to come to 
future visits as planned, every  attempt will be made to get information on vital status at week 
24 after his/her randomization.
Patients will be asked to agree to be contacted b y the site personnel, whi ch could be by  
telephone calls, to allow collection of this information.
If death occurs, the investigator will review the circumstances, including the relevant medical 
records to ascertain the most likely  primary  and secondary  causes of death.
Collection of vital status will be performed in accordance with national ethical and regulatory  
guidelines. The need for vital status information will be explained to patients prior to their 
participation in the trial.
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 57of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
7. STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
STATISTICAL DESIGN - MODEL 7.1
This is a double -blind, randomized, parallel -group study  stratified b y presence of any 
echocardiographic signs indicative of right heart dy sfunction to evaluat ethe efficacy  and 
safet y of nintedanib when co -administered with sildenafil, compared to treatment with 
nintedanib alone, in patients with idiopathic pulmonary  fibrosis (IPF) and advanced lung 
function impairment .
The primary  endpoint is the change from baseline in SGRQ total score at week 12.
The primary  endpoint will be anal ysed using a Mixed Effects Model for Repeated Measures 
(MMRM) .The details are provided in section 7.3.1.
The secondary  endpoint s related to SGRQ and UCSD SOBQ will be analy sed using MMRM. 
Details are provided in section 7.3.2.
The secondary  endpoint p ercentage of patients with on-treatment SAEs from baseline to 
week 24 will be anal ysed using the Cochran- Mantel -Haenszel test exploratorily .
Analy sis of further endpoints is described in section 7.3.3.
NULL AND ALTERNATIVE HYPOTHESES 7.2
The objective of this study , demonstrating a n additional treatment effect of nintedanib co-
administered with sildenafil compared to treatment with nintedanib alone, in patients with 
idiopathic pulmonary  fibrosis (I PF) and advanced lung function impairment will be tested 
using the following null hy pothesis:
H0: There is no difference in the mean change from baseline in SGRQ total score at 
week 12 between nintedanib co-administered with sildenafil compared to treatment 
with nintedanib.
The alternative hy pothesis is
Ha: There is a difference in the mean change from baseline in SGRQ total score at 
week 12 between nintedanib co-administered with sildenafil compared to treatment 
with nintedanib.
A hierarchical testing procedure will be applied in order to allow for confirmative testing of 
the secondary  endpoint s related to SGRQ and UCSD SOBQ also. This procedure is specified i n 
Table 7.2:1 .
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 58of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Table 7.2:1 Flow of h ypothesis testing
Step 1 If H 0is rejected at 5% level (two- sided test) then go to the next step otherwise 
procedure is stopped and subsequent tests will be done only  for exploratory  
purposes .
Step 2 H01: There is no difference in the mean change from baseline in UCSD SOBQ 
at week 12 between nintedanib co -administered with sildenafil compared to 
treatment with nintedanib.
Ha1: There is a difference in the mean change from baseline in UCSD SOB Q at 
week 12 between nintedanib co- administered with sildenafil compared to 
treatment with nintedanib.
If H 01is rejected at 5% level (two -sided test) then go to the next step otherwise 
procedure is stopped and subsequent tests will be done only  for exploratory  
purposes.
Step 3 H02: There is no difference in the mean change from baseline in SGRQ total 
score at week 24 between nintedanib co -administered with sildenafil compared 
to treatment with nintedanib.
Ha2: There is adifference in the mean change from baseline in SGRQ total 
score at week 24between nintedanib co -administered with sildenafil compared 
to trea tment with nintedanib.
If H 02is rejected at 5% level (two -sided test) then go to the next step otherwise 
procedure is stopped and subsequent tests will be done only  for exploratory  
purposes.
Step 4 H03: There is no difference in the mean change from base line in UCSD SOBQ 
at week 24between nintedanib co -administered with sildenafil compared to 
treatment with nintedanib.
Ha3: There is a difference in the mean change from baseline in UCSD SOBQ at 
week 24between nintedanib co -administered with sildenafil compared to 
treatment with nintedanib. 
The hy potheses will be tested using 5% level of significance (two- sided test). Global ty pe I 
error will be not exceed 5% within this procedure, thus no adjustment for multiplicity  is 
required. 
Statistical tests perfo rmed for an y other endpoints not included in the above defined testing 
procedure will also be done only  for exploratory  purposes.
PLANNED ANALYSES 7.3
The statistical anal ysis will be based on the Treated Set (TS), which consists of patients who
are randomised to a treatment group and receive at least one dose of randomised study
medication. 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 59of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Most analy ses will be based on the treatment group (nintedanib only  or nintedanib co -
administered with sildenafil) as randomized. Safety  parameters will be analy zedfrom an as 
treated perspective.
Although there is no per protocol set in the study , reasons for important protocol violations
will be specified in the Trial Statistical Analysis Plan (TSAP). Patients with potential
important protocol violations (those that relate to patient safet y) will be identified at Blinded 
Review Planning Meetings and listed in the CTR and their impact will be evaluated .
7.3.1 Primary  endpoint anal yses
Change from baseline in SGRQ total score at week 12 will be anal ysed using REML based
MMRM. 
The model will include fixed effect for treatment , visit andpresence of an y 
echocardiographic signs indicative of right heart dy sfunction including right ventricular 
hypertrophy  and right ventricular or atrial dilatation (as described in section 6.2.1 ), 
baseline 
SGRQ total score as a covariate and treatment -by-visit and baseline- by visit as interaction 
terms . Baseline SGRQ total score will be measured at visit 2. No imputation is planned if this 
assessment is not a vailable for a patient. A n unstructured (co)variance matrix will be used to 
model the within -patient measurements. In case there is a lack of convergence, a Compound 
Symmetry  
(co)variance matrix will be used .The Roger -Kenward approximation will be used 
toestimate denominator degrees of freedom. Data collected after visit 5 (planned 12 weeks 
after start of study  treatment) will not be used for this analy sis. Analy ses will be implemented 
using SAS®Version 9.4 or higher .The primary  treatment comparisons will be the contrast 
between treatments at 12 weeks.
Sensitivity  analy sis: The effect of missing data will also be investigated using tipping point
sensitivity  anal yses. The technique will be detailed in the TSAP. The effect on the following 
subgroups will be explored
:
sex (female/male)
age (<65, ≥65 y ears)
race (White, Asian, Other)
baseline FVC % predicted (<50%, ≥50%)
baseline St. George’s Respiratory Questionnaire (SGRQ) total score ( ≤40, >40)
presence of an y echocardiographic signs indicative of right heart dy sfunction (y es/no)
Within subgroup anal yses, subgroup (if not already  included in the primary anal ysis model) 
and treatment subgroup interaction effect will be added to the primary  analy sis model. The 
treatment subgroup interaction effect will be of primary  interest for subgroup anal yses. 
As needed, further details and/or further subgroups will be defined and described in the Trial 
Statistical Analy sis Plan.
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 60of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
7.3.2 Secondary  endpoint analy ses
Change from baseline in U CSD SOBQ at week 12 will be anal ysed using the same method as 
the primary  endpoint , but with baseline UCSD SOBQ instead of SGRQ total score as 
covariate .Data collected after visit 5 (planned 12 weeks after start of study treatment) will 
not be used for this anal ysis.
Both changes from baseline in SGRQ and UCSD SOBQ at week 24 will be anal ysed as in the 
respective week 12 anal ysis. For these anal yses, data collected from the complete 24 weeks 
treatment period will be used.
Percentage sof patients with on- treatment SAEs from baseline to week 24 will be compared 
using the Cochran -Mantel -Haenszel test adjusting for the categorical covariate presence of 
any echocardiographic signs indicative of right heart dy sfunction (y es/no) . Adjusted Ma ntel-
Haenszel ty pe risk ratios and risk differences with 95% confidence intervals will be used to 
quantify  the treatment effect for the comparison between treatment groups.

Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 61of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
7.3.4 Safety  anal yses
Analy sis of key  safet y endpoints is described in sections 7.3.2 and 7.3.3.
Adverse events will be coded using the Medical Dictio nary for Regulatory  Activities
(MedDRA) coding dictionary . Standard BI summary  tables and listings will be produced. All 
adverse events with an onset between start of treatment and end of the residual effect period 
(REP), a period of 28 daysafter the last dose of trialmedication ,willbe assigned to the 
treatment period for evaluation.
All treated patients will be included in the safet y analysis. In general, safet y anal yses will be 
descriptive in nature and will be based on BI standards. No hypothesis testing is planned.
Statistical analy sis and reporting of adverse events will concentrate on treatment -emergent 
adverse events. To this end, all adverse events occurring between start of treatment and end 
of the residual effect period will be co nsidered ‘treatment-
emergent’.  The residual effect 
period is defined as 28 day s. Adverse events that start before first drug intake and deteriorate 
under treatment will also be considered as ‘treatment- emergent’.
Frequency , severit y, and causal relationsh ipof adverse events will be tabulated by system 
organ class and preferred term after coding according to the current version of the Medical 
Dictionary  for Drug Regulatory  Activities (MedDRA).
Laboratory  data will be analy sedboth quantitatively  as well a s qualitatively. The latter will 
be done via comparison of laboratory data to their reference ranges. Values outside the 
reference range ,as well as values defined as clinically  relevant ,will be highlighted in the 
listings. Treatment groups will be compared descriptively  with regard to distribution 
parameters as well as with regard to frequency  and percentage of patients with abnormal 
values or clinicall y relevant abnormal values.
Vital s igns, ph ysical examinations, or other safet y
-relevant data observed at screening, 
baseline, during the course of the trial and at the end -of-trial evaluation will be assessed with 
regard to possible changes compared to findings befo re start of treatment.
 
 
 
 
 
 

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 62of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
 
 
 
 
 
 
 
 
 
 
 
INTERIM ANALYSES 7.4
No interim anal ysis is planned but the conduct of the trial will be monitored by  a DMC.
HANDLING OF MISSING DATA 7.5
In efficacy  anal yses of continuous endpoints missing data will not be imputed. In the analy ses
of the time -to-event endpoints, missing or incomplete data are managed by  standard survival
analysis techniques. These will be described in detail in the TSAP.
Missing or incomplete AE dates will be imputed according to BI standards . With respect to 
other safet y evaluations, it is not planned to impute missing values.
In pharmacokinetic analyses, missing data will not be imputed. Descriptive statistics of 
concentrations at specific time points will be calculated only  when at least 2/3 of the 
individuals have concentrations within the validated concentration range. The overall sample 
size to decide whether the “2/3 rule” is fulfilled will be based on the total number of samples 
intended to be drawn for that time point (i.e. BLQ, NOR, NOS, and NOA are included). 
Descriptive statistics of parameters are also calculated only  when at least 2/3 of the individual 
parameter estimates of a certain parameter are available. If the actual sampling time is not 
recorded or is missing for a certain time point, the planned time will generally  be used for this 
time point instead.
RANDOMISATION 7.6
Patients will be stratified by  the presence of anyechocardiographic signs indicative of right 
heart d ysfunction including right ventricular hy pertrophy  and right ventricular or atrial 
dilatation (as described in section 6.2.1 )and will be randomized in blocks to double -blind 
treatment . Approximately  equal numbers of patients will be randomized to each treatment 

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 63of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
group. BI will arrange for the randomization and the packaging and labelling of trial
medication. The randomization listswill be generated u sing a validated s ystem, which 
involves a pseudo- random number generator so that the resulting treatment will be both 
reproducible and non -predictable. The block size will be documented in the CTR. Access to 
the codes wil l be controlled and documented.
DETERMINATION OF SAMPL E SIZE 7.7
The hy pothesis for expected difference in the change from baseline in SGRQ total score at 
week 12 is -4.5 units between nintedanib co-administered with sildenafil compared to 
treatment with nintedanib alone using a two group t -test with a 0.025 one -sided significance 
level.
The assumed difference is based on observations made in the INPULSIS®trials, where the 
observed mean change from baseline to week 12 in SGRQ total score when treated with 
nintedanib alo ne was 0.75/0.05 units with a standard deviation of 12.93/11.64 (INPUL SIS®-
1/INPULSIS®-2).
Based on the STEP -IPF trial [ R12-3686], the mean change from baseline to week 12in 
SGRQ total score when treated with sildenafil alone was -4.08 units with an estimated 
standard deviation of 11. 02 units. I t is assumed that the observed treatment effect remains 
stable when nintedanib is co- administered with sildenafil.
Therefore , power calculations are made based on the assumption of equal standard deviations 
among groups and an expected difference of - 4.5 units.
Table 7.7: 1 presents the different scenarios for the sample size calculation.
Table 7.7: 1 Sample size calculations for difference in the change from baseline in SGRQ 
total score at week 12 assuming a group difference of - 4.5 units for several 
standard deviations and a 1:1 randomisation ratio using a two group t -test with a 
0.025 one- sided significance level. 
Standard deviation N per group Total sample size
80% power
11 95 190
12 113 226
13 132 264
90% power
11 127 254
12 150 300
13 177 354
So, a sample size of 125 patients in both groups will have about 90% power to detect a
difference in means of -4.5 units in change from baseline in SQRG total score assuming that 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 64of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
the common standard deviation is 11 units using a two group t -test with a 0,025 one -sided 
significance level.
As we use a mixed model, including adjustment for several variable , this sample size based 
on t-test should provide at l east 90% power.
Calculations were performed using nQuery  Advisor®6.1 statistical package by  Statistical 
Solutions L td.
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 65of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
8. INFORMED CONSENT, DA TA PROTECTION, TRIAL
RECORDS
The trial will be carried out in compliance with the protocol, the ethical principles l aid down 
in the Declaration of Helsinki, in accordance with the I CH Harmonized Tripartite Guideline 
for Good Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs) , and 
relevant regulations and the Japanese GCP regulations (Ministry  of H ealth and Welfare 
Ordinance No. 28, March 27, 1997) only for Japan.
Standard medical care (prophy lactic, diagnostic and therapeutic procedures) remains in the 
responsibility  of the treating phy sician of the patient.
The Investigator will inform the sponsor immediately  of any  urgent safet y measures taken to 
protect the trialsubjects against any  immediate hazard, and also of an y serious breaches of 
the protocol or of ICH GCP.
The rights of the Investigator and of the s ponsor with regard to publication of the results of 
this trial are described in the Investigator contract. As a rule , no trial results should be 
published prior to finalization of the Clinical Trial Report.
For Japan only :The rights of the investigator / trial site and of the sponsor with regar d to 
publication of the results of this trial are described in the investigator contract / trial site’s 
contract. As a general rule, no trial results should be published prior to finalisation of the 
Clinical Trial Report.
The certificate of insurance cover ismade available to the Investigator and the patients, and is
stored in the I SF (Investigator Site File).
TRIAL APPROVAL, PATIENT IN FORMATION, AND INFOR MED 8.1
CONSENT
This trial will be initiated only  after all required legal documentation has been reviewed and 
approved b y the respective Institutional Review Board (IRB) / Independent Ethics Committee 
(IEC) and competent authority  (CA) according to national and international regulations. The 
same applies for the implementation of changes introduced by amendments.
Prior to patient participation in the trial, written informed consent must be obtained from each 
patient (or the patient’s legally accepted representative) according to ICH / GCP and to the 
regulatory  and legal requirements of the participatin g country . Each signature must be 
personall y dated b y each signatory  and the informed consent and any  additional patient-
information form retained by  the Investigator as part of the trial records. A signed copy  of the 
informed consent and any  additional pa tient information must be given to each patient or the 
patient’s legall y accepted representative.
For Japan only :The Investigator must give a full explanation to trial patients including the 
items listed below in association with the use of the patient i nformation form, which is 
prepared avoiding the use of technical terms and expressions. The patient is given sufficient 
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 66of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
time to consider participation in the trial. The Investigator obtains written consent of the 
patient’s own free will with the informed c onsent form after confirming that the patient 
understands the contents. The Investigator must sign (or place a seal on) and date the 
informed consent form. If a trial collaborator has given a supplementary  explanation, the trial 
collaborator also signs (or places a seal on) and dates the informed consent.
Re-consenting may become necessary  when new relevant information becomes available and 
should be conducted according to the sponsor’s instructions.
DATA QUALITY ASSURANCE 8.2
A quality  assurance audit/inspection of this trial may  be conducted by  the s ponsor , sponsor ’s 
designees ,or by IRB /IECor by  regulatory  authorities. The quality  assurance auditor will 
have access to all medical records, the Investigator ’s trial -related f iles and correspondence, 
and the informed consent docume ntation of this clinical trial.
RECORDS 8.3
Electronic Case Report Forms (e)CRF for individual patients will be provided by  the sponsor .
See section 4.1.5.2 for rules about emergency  code breaks. For drug accountability , refer to 
section 4.1.8 .
8.3.1 Source documents
Source documents provide evidence for the existence of the patient and substantiate the 
integrit y of the data collected. S ource documents are filed at the Investigator ’s site.
Data reported on the CRF must be consistent with the source data or the discrepancies must 
be explained. The Investigator may need to request previous medical records or transfer 
records, depending on t he tria l;current medical records must also be available.
For eCRFs all data must be derived from source documents.
8.3.2 Direct access to source data and documents
The Investigator / institution will permit trial -related monitoring, audits, IRB / IEC review 
and regulatory  inspection, providing direct access to all related source data / documents. 
CRF/eCRF and all source documents, including progress notes and copies of laboratory  and 
medical test results must be available at all times for review b y the sponsor ’s clinical trial 
monitor, auditor and inspection by health authorities (e.g. FDA). The Clinical Research 
Associate (CRA) / on site monitor and auditor may review all CRF /eCRF , and written 
informed consents. The accuracy  of the data will be verified by  reviewing the docume nts 
described in section 8.3.1.
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 67of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
8.3.3 Storage period of records
For Japan only :
Trial site(s): The trial site(s) must retain the source documents and essential documents for a 
period defined b y the Japanese GCP regulation and trial site’s contract with the sponsor.
Sponsor: The sponsor must retain the essential documents according to the sponsor ’s SOPs.
When it is no longer necessary  for the trial site to retain the source documents and essential 
documents, the sponsor must notify  the head of trial site.
LISTEDNESS AND EXPEDITED REPORTING OF AD VERSE EVENTS 8.4
8.4.1 Listedness
To fulfil the regulatory  require ments for expedited safet y reporting, the sponsor evaluates 
whether a particular adverse event is "listed", i.e. is a known side effect of the drug or not. 
Therefore, a unique reference document for the evaluation of listedness needs to be provided. 
For the nintedanib this is the current version of the I nvestigator’s Brochure [U07-1248].
For sildenafil the EU SmPC (Revatio®)serves as refere nce document .
The current versions of these reference documents are provided in the I SF. No AEsare 
classified as listed for matching placebo, trialdesign, or invasive procedures.
8.4.2 Expedited reporting to health authorities and IEC /IRB
Expedited reporting of serious adverse events, e.g. suspected unexpected serious adverse 
reactions (SUSAR) to health authorities and IEC /IRB, will be done according to local 
regulatory  requirements.
STATEMENT OF CONFIDE NTIALITY 8.5
Individual patient medical information obtained as a result of this trial is considered 
confidential and disclosure to third parties is prohibited with the exceptions noted below. 
Patient confidentiality  will be ensured by  using patient identification code numbers.
Treatment data may  be giv en to the patient’s personal phy sician or to other appropriate 
medical personnel responsible for the patient’s welfare. Data generated as a result of the trial 
need to be available for inspection on request b y the participating ph ysicians, the s ponsor ’s 
representatives, by  the IRB / IEC and the regulatory  authorities.
END OF TRIAL 8.6
The end of the trial is defined as the date of the last visit of the last patient in the whole trial 
(“Last Patient Out”). 
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 68of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
The IEC/competent authority  in each participating EU member state will be notified about 
the end or early termination of the trial.
For Japan only :When the trial is completed, the Investigator should inform the head of the 
trial site of the completion in writing , and the head of the trial site should promptly  inform the 
IRB and sponsor of the completion in writing.
PROTOCOL VIOLATIONS 8.7
For Japan only :The investigator should document any  deviation from the protocol regardless 
of their reasons. Onl y when the protocol was not followed in order to avoid an immediate 
hazard to trial subjects or for other medically  compelling reason, the principal investigator 
should prepare and submit the records explaining the reasons thereof to the sponsor, and 
retain a cop y ofthe records.
COMPENSATION AVAILAB LE TO THE PATIENT IN THE EVENT OF 8.8
TRIAL RELATED INJURY
For Japan only :In the event of health injury associated with this trial, the sponsor is 
responsible for compensation based on the con tract signed by  the trial site.
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 69of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
9. REFERENCES
PUBLISHED REFERENCES 9.1
P05-12782 Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, 
Enright P, Grinten CPM van der, Gustafsson P, Jensen R, Johnson DC, MacIntyre 
N, McKay  R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J . 
Standardisation of spirometry .Eur Respir J 26 (2), 319 - 338 (2005)
P08-08684 Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch -Grunt 
U, Garin -Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ BIBF 
1120: triple angiokinase inhibitor with sustained receptor blockade and good 
antitumor efficacy .Cancer Res 68 (12), 4774 -4782 (2008)
P11-00203 Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P,
Pawel J von. A phase II double -blind study  to investigate efficacy  and safety  of 
two doses of the triple angiokinase inhib itor BIBF 1120 in patients with relapsed 
advanced non -small -cell lung cancer. Ann Oncol 22 (6), 1374 – 1381 (2011)
P11-07084 Raghu G, et al, ATS/ERS/JRS/AL AT Committee on I diopathic Pulmonary  
Fibrosis .  
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary  
fibrosis: evidence -based guidelines for diagnosis and management. Am J Respir 
Crit Care Med 183 (6), 788 -824 (2011)
P11-10116 Ledermann JA, Hackshaw A, Kay e S, Jay son G, Gabra H, McNeish I, Earl H, 
Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin 
G.  Randomized phase II placebo -controlled trial of maintenance therap y using 
the oral triple angiokinase inhibitor BIBF 1120 after chemotherap y for rel apsed
ovarian cancer.   45th Ann Mtg of the American Society  of Clinical Oncology
(ASCO), Orlando, 29 May -2 Jun 2009 J Clin Oncol 29 (28), 379838 (2011)
P11-11216 Richeldi L , Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, 
BrownKK, Flahert y KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, 
Klueglich M, Bois RM du Efficacy  of a t yrosine kinase inhibitor in idiopathic 
pulmonary  fibrosis. N Engl J Med 365 (12), 1079 - 1087 (2011)
P12-06085 Idiopathic Pulmonary  Fibrosis Clinical Research Network Prednisone, 
azathioprine, and N -acety lcysteine for pulmonary fibrosis. N Engl J Med 366 
(21), 1968 - 1977 (2012)
P13-06268 Eisen T, Shpary k Y, Jones R, MacLeod NJ, Temple G, Finnigan H, Kaiser R, 
Studeny  M, Loembe AB, Bondarenko I Phase II efficacy  and s afety study of 
nintedanib versus sunitinib in previously  untreated renal cell carcinoma (RCC) 
patients. 49th Ann Mtg of the Americ an Societ y of Clinical Oncology (ASCO),
Chicago, 31 May  -4 Jun 2013 J Clin Oncol 31 (Suppl), Abstr 4506 (2013)
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 70of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
P13-12693 Yen CJ, Kim TY, Feng YS, Chao Y, L in DY, Studeny  M, Hocke J, Huang 
DCL ,Ryoo BY, Cheng AL Efficacy  and safet y of nintedanib versus sorafenib 
in Asian patients with advanced hepatocellular carcinoma: a randomised phase 
II trial. 38th Ann Cong of the European Societ y for Medical Oncology 
(ESMO), Amsterdam, 27 Sep - 1 Oct 2013 (Poster) 
P14-02860 Wollin L , Maillet I, Quesniaux V, Holweg A, R yffel B Anti- fibrotic and anti -
inflammatory  activity  of the ty rosine kinase inhibitor, nintedanib, in 
experimental models of lung fibrosis. J Pharmacol Exp Ther 349, 209 - 220 
(2014)
P14-
07514 Richeldi L , et al, INPULSI S Trial Investigators. Efficacy  and safet y of 
nintedanib in idiopathic pulmonary  fibrosis. N Engl J Med 370 (22), 2071 -
2082 (2014)
P14-07665 Idiopathic P ulmonary  Fibrosis Clinical Research Network Randomized trial of 
acetylcysteine in idiopathic pulmonary  fibrosis. N Engl J Med 370 (22), 2093 -
2101 (2014)
P14-08020 Scagliotti GV, Leighl NB, Nowak AK, Pavlakis N, Popat S, Sorensen JB, 
Barrueco J, Kaiser R, Loembe AB, Mueller M, Wangenheim U von, Reck M
Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for 
unresectable malignant pleural mesothelioma (MPM): an international, 
multicenter, randomized, double- blind, placebo -controlled pha se II stud y.50th 
Ann Mtg of the American Society  of Clinical Oncology  (ASCO), Chicago, 30 
May -3 Jun 2014
P15-07362 Raghu G, et al, ATS, ERS, JRS, and AL AT An official ATS/ERS/JRS/ALAT 
clinical practice guideline: treatment of idiopathic pulmonary  fibro sis: 
executive summary : an update of the 2011 clinical practice guideline. Am J 
Respir Crit Care Med 192 (2), 238 -248 (2015)
P15-09876 Crestani B, Ogura T, Pelling K, Coeck C, Quaresma M, Kreuter M, Kay e M 
Interim anal ysis of nintedanib in an open- label extension of the INPUL SIS 
trials (INPUL SIS-ON). 25th Ann Cong of the European Respiratory  Society  
(ERS), Amsterdam, 26 - 30 Sep 2015
P16-06899 Collard HR, Ry erson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al
Acute exacerbation of idiopathic pulmonary  fibrosis: an international working 
group report. Am J Respir Crit Care Med, (2016)
R06-2002 Macinty re N, Crapo RO, Viegi G, Johnson DC, Grinten CPM van der, 
Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, 
Hankinson J, Jensen R, McKay  R, Miller MR, Navajas D, Pedersen OF, 
Pellegrino R, Wanger J Standardisation of the single -breath determination of 
carbon monoxide uptake in the lung. Eur Respir J 26 (4), 720 - 735 (2005)
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 71of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
R06-2070 Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Na kata K, Taguchi Y, Nagai 
S, Itoh H, Ohi M, Sato A, Kudoh S, Research Group for Diffuse Lung 
Diseases in Japan, Raghu G Double -blind, placebo -controlled trial of 
pirfenidone in patients with idiopathic pulmonary  fibrosis.Am J Respir Crit 
Care Med 171, 1040 – 1047 (2005)
R10-4316 Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, 
Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T,
Pirfenidone Clinical Study  Group in Japan . Pirfenidone in idiopathic 
pulmonary fibrosis. Eur Respir J 35 (4), 821 - 829 (2010)
R10-4848 Common terminology  criteria for adverse events (CTCAE): version 4.0 (NIH 
publication no. 09- 5410, published: May  28, 2009 (v4.03: June 14, 2010), 
revised June 2010, reprinted June 2010).
http://evs.nci.nih.gov/f
tp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_8.5x11.pd f (2010)
R11-
4827 Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, 
King TE, Lancaster L, Sahn SA, Szwarcberg J, Valey re D, Bois RM du, 
CAPACI TY Study  Group . Pirfenidone in pa tients with idiopathic pulmonary  
fibrosis (CAPACI TY): two randomised trials. Lancet 377, 1760 -1769 (2011)
R11-
5086 Thabut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, Fournier M, 
Leseche G, Porcher R, Mal HSurvival after bilateral versus single -lung
transplantation for idiopathic pulmonary  fibrosis. Ann Intern Med 151 (11), 
767 - 774 (2009)
R12-
2785 Keating D, Levvey  B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell 
G. Lung transplanation in pulmonary  fibrosis: challenging earl y outcomes 
counterbalanced b y surprisingly  good outcomes bey ond 15 y ears. Transplant 
Proc 41, 289 
-291 (2009)
R12-2786 Kim DS, Collard HR, King TE Classification and natural history  of the 
idiopathic interstitial pneumonias. Proc Am Thorac Soc 3, 285 - 292 (2006)
R12-3474 Kotloff RM, Thabut G Lung transplantation. Am J Respir Crit Care Med 184, 
159 - 171 (2011)
R12-
3676 McCurry  KR, Shearon TH, Edwards LB, Chan KM, Sweet SC, Valapour M, 
Yusen R, Murray  S, Lung transplantation in the United States, 1998 
- 2007. 
Am J Transplant 9, 942 - 958 (2009)
R12-3686 Idiopathic Pulmonary  Fibrosis Clinical Research Network. A controlled trial 
of sildenafil in advanced idiopathic pulmonary  fibrosis. N Engl J Med 363 (7), 
620 - 628 (2010)
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 72of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
R14-2103 King TE, Bradford WZ , Castro -Bernardini S, Fagan EA, Glaspole I, Glassberg 
MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L , Lederer DJ, Nathan 
SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study  
Group A phase 3 trial of pirfenidone in patients with idiopathic pulmonary  
fibrosis. N Engl J Med 370 (22), 2083 -2092 (2014)
R15-5445 Pulido T, Adzerikho I , Channick RN, Delcroix M, Galie N, Ghofrani HA, 
Jansa P, Jing ZC, Brun FO Le, Mehta S, Mittelholzer CM, Perchenet L, Sastry  
BKS, Sitbon O, Souza R, Torbic ki A, Zeng X, Rubin L J, Simonneau G, 
SERAPHI N Investigators Macitentan and morbidity  and mortalit y in 
pulmonary  arterial hy pertension. N Engl J Med 369 (9), 809 -818 (2013)
R15-5446 McLaughlin V, Channick RN, Ghofrani HA, Lemarie JC, Naeije R, Packer M, 
Souza R, Tapson VF, Tolson J, Hiti H al, Mey er G, Hoeper MM Bosentan 
added to sildenafil therapy  in patients with pulmonary  arterial h ypertension. 
Eur Respir J 46, 405 -413 (2015)
R15-5447 Ghofrani HA, Humbert M The role of combination therap y in managin g 
pulmonary  arterial hy pertension. Eur Respir Rev 23, 469 -475 (2014)
R96-0690 Cockcroft DW, Gault MH Prediction of creatinine clearance from serum 
creatinine. Nephron 16 (1), 31 -41 (1976)
UNPUBLISHED REFERENC ES 9.2
U07-1248  Investigator’s brochure: Nintedanib (BIBF1120), Indication: 
Idiopathic P ulmonary  Fibrosis. 1199.P3. Ve rsion 10. 23 Sep 2015.

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 73of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
10. APPENDICES
CRITERIA FOR HRCT/BIOPSY REVIEW 10.1
The following criteria should be assessed at screening for all patients based on a HRC T scan 
performed within 18 months of visit 1:
A)      Definite honey comb lung destruction with basal and peripheral predominance.
B)      Presence of reticular abnormality AND traction bronchiectasis consistent with 
fibrosis with basal and peripheral predo minance. 
C)      Aty pical features are ABSENT, specificall y: nodules and consolidation. Ground 
glass opacity , if present, is less extensive than reticular opacit y pattern.
Patients with HRCT meeting either criteria A, B and C, or criteria A and C, or criteria B and 
C are eligible for this trial without the need of a surgical lung biops y.
In the presence of a surgical lung biops y, the histology  should be reviewed based on the 
ATS/ERS/JRS/AL AT guidelines [ P11-07084]. An HRCT pattern "possible UIP" coupled 
with a surgical biopsy  
pattern “definite UI P” or "probable UIP", upon multidisciplinary  team 
discussion, could qualify for inclusion as “consistent with a diagnosis of IPF”.
CREATININE CLEARANCE 10.2
Creatinine clearance calcula tion is done according to Cockroft and Gault [ R96-0690].
Creatinine clearance = (140 - age) x (Weight in kg) x (0.85 if female) / (72 x serum creatinine 
in mg/dL)
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 74of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
ST GEORGE’S RESPIRAT ORY QUESTIONNAIRE (S GRQ ) 10.3

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 75of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 76of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 77of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 78of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 79of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 80of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
THE UCSD SHORTNESS O F BREATH QUESTIONNAIRE (UCSD - 10.4
SOBQ )

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 81of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 82of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 83of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 84of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
EUROQOL -5D  (EQ -5D) 10.5
By placing a checkmark in one box in each group below, please indicate which 
statements best describe your own health state today.
Mobility
I have no problems in walking about 
I have som e problems in walking about 
I am confined to bed 
Self-Care
I have no problems with self -care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
Usual A ctivities (e.g. work, study, housework, family or
leisure activities)
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
Pain/Discomfort
I have no pain or discomfort 
I have moderate pain or disc omfort 
I have extreme pain or discomfort 
Anxiety /Depression
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 85of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies

Boehringer Ingelheim 18 A ug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 86of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
DLCO 10.6
For predicted normal values, different sites may  use different prediction formulas, based on 
the method used to measure DLCO. In an y case, the method used must be in compliance with 
the ATS/ERS guideline on DL CO measurements [ R06-2002] , and the prediction formula 
appropriate for that method. Raw data (gas mixture, equation used for prediction of normal, 
further adjustments made if so) must be traced.
Predicted DLCO corrected for haemoglobin (Hb) expressed in g x dL-1(R06-2002) can be 
calculated as:
Predicted DLCO corrected for Hb = Predicted DLCO x (1.7Hb/(10.22+Hb)) for males 
Predicted DLCO corrected for Hb = Predicted DLCO x (1.7Hb/(9.38+Hb)) for 
females 
For decision on inclusion / excl usion, DL CO results from Visit 1 willbe corrected for 
haemoglobin (value obtained at v isit 1) by  the site. 
For analy sis of the trial data, DLCO results will be corrected for haemoglobin by  central data 
management. This means that the site has to enter the DLCO results without haemoglobin 
correction in the eCRF, at all visits.
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 87of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
11. DESCRIPTION OF GLOBA L AMENDMENT(S)
Number of global amendment 1
Date of CTP revision 04 Mar ch2016
EudraCT number 2015-002619-14
BI Trial number 1199.36
BI Investigational Product(s) nintedanib
Title of protocol A 24 -week, double -blind, randomized, parallel -
group stud y evaluating the efficacy and safet y of 
oral nintedanib co-administered with oral 
sildenafil, compared to treatment with nintedanib 
alone, in patients with idiopathic pulmonary  
fibrosis (I PF) and advanced lung function 
impairment
To be implemented only after 
approval of the IRB /IEC /
Competent AuthoritiesYes
To be implemented 
immediately in order to 
eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
change with request for 
approvalNo
Can be implemented without 
IRB /IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects onlyNo
Section to be changed Section 1.2.2 Sildenafil
Description of change Potential risks of treatment with sildenafil include 
hypotension, worsening of pulmonary vascular 
occlusive disease, epistaxis, visual loss, hearing 
loss, priapism and vaso -occlusive crisis in patients 
with pulmonary  hypertension secondary  to sickle 
cell disease.
Was changed to:
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 88of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Potential risks of treatment with sildenafil include 
hypotension, worsenin g of pulmonary  veno -
occlusive disease, epistaxis, visual loss, hearing 
loss, priapism and vaso -occlusive crisis in patients 
with p ulmonary  hypertension secondary  to sickle 
cell disease .
Rationale for change Rewording .
Section to be changed Section 2.3 Benefit – Risk assessment
Description of change Potential risks of treatment with sildenafil include 
hypotension, worsening of pulmonary vascular 
occlusive disease, epistaxis, visual loss, hearing 
loss, priapism and vaso -occlusive crisis in patients 
with pulmonary  hypertension secondary  to sickle 
cell disease. Patients at higher risk for these 
conditions are excluded from this trial.
Was changed to:
Potential risks of treatment with sildenafil include 
hypotension, worsening of pulmonary  veno -
occlusive disease, epistaxis, visual loss, hearing 
loss, priapism and vaso -occlusive crisis in patients 
with p ulmonary  hypertension secondary  to sickle 
cell disease . Patients at higher risk for these 
conditions are excluded from this trial.
Rationale for change Rewording
Section to be changed Section 3.3 Selection of trial population
Description of change A total of approximately  250 patients with an I PF 
diagnosis and advanced lung function impairment 
will be randomized. Approximately  60 sites are 
each expected to include approximately  4 patients.
Was changed to:
A total of approximately  250 patients with an I PF 
diagnosis and advanced lung function impairment 
will be randomized. Approximately  80 sites are 
each expected to include approximately  3 patients. 
Rationale for change Number of participating sites (increase) and 
average number of patients per site (decrease) 
adjusted following site feasibility .
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 89of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Section to be changed Section 3.3.3 E xclusion criterion and 
abbreviations
Description of change In exclusion criterion #6 Partial Thromboplastin 
Time (PTT) was replaced by  Activated Partial 
Thromboplastin Time. The same has been 
corrected in the Abbreviations section.
Rationale for change Correction / rewording 
Section to be changed Section 3.3.3 Exclusion criterion
Description of change Exclusion criterion #34 has been added:
Patients with underly ing chronic liver disease 
(Child Pugh A, B or C hepatic impairment)
Rationale for change Based on interactions with regulatory  authorities 
including the FDA, the recommended dosage of 
nintedanib for patients with Child Pugh A hepatic 
impairment is 100 mg bid which has been recently 
included int o the US Prescribing Information. As 
in the current protocol all patients should initiate 
treatment with the same starting dose of 
nintedanib 150 mg bid, patients with Child Pugh A 
will be excluded. I n addition, patients with Child 
Pugh B and C hepatic impairment will also be 
excluded to again be in line with the information 
stated in the US Prescribing Information that 
treatment with nintedanib in these patients is not 
recommended.
Section to be changed
Section 5.4.1 Assessment of Pharmacokinetics; 
Section 5.4.2 Methods of sample collection and 
Section 5.4.3 Analy tical determinations
Description of change
5.4.1 Assessment of Pharmacokinetics

Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 90of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Pre-dose plasma samples of nintedanib and its 
metabolites, BIBF 1202 and BIBF 1202
glucuronide, will be taken according to the flow 
chart.
Was changed to:
Pre-dose plasma samples of nintedanib will be 
taken according to the flow chart .
5.4.2 Methods of sample collection
A detailed description of sample collection and 
handling is provided in the I SF/lab manual. For 
quantification of drug plasma concentrations of 
nintedanib (BIBF 1120) and its metabolites BIBF 
1202 and BIBF 1202 -glucuronide, venous blood 
will be collected using a pre-labeled potassium 
ethylenediamine -tetraacetic acid (EDTA) 
containing blood drawing tube. The obtained 
plasma will be transferred into 1 vial (at least 0.5 
mL plasma). After completion of the study , the 
plasma samples may  be used for further 
methodological investigations, e.g. stability  
testing. However, onl y data related to nintedanib 
and/or its metabolite(s) will be generated b y these 
additional investigations.
Was changed to:
A detailed description of sample collection and 
handling is provided in the I
SF/lab manual. For 
quantification of drug plasma concentrations of 
nintedanib, venous blood will be collected using a 
pre-labeled potassium ethy lenediamine -tetraacetic 
acid (EDTA) containing blood drawing tube. The 
obtained pl asma will be transferred into 1 vial (at 
least 0.5 mL  plasma).
After completion of the study , the plasma samples 
may be used for further methodological 
investigations, e.g. stability  testing. However, onl y 
data related to nintedanib will be generated by  
these additional investigations.
5.4.3 Analy tical determinations
Nintedanib (in form of its free base BIBF 1120 
BS), its metabolites BIBF 1202 (in form of the 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 91of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
free zwitterion BIBF 1202 ZW) and the 
acylglucuronid thereof (BIBF 1202 glucuronide)
plasma concentrations will be determined b y a 
validated assay  based on liquid chromatograph y-
tandem mass spectrometry (LC- MS/MS).
Was changed to:
Nintedanib (in form of its free base BIBF 1120 
BS)plasma concentrations will be determined b y a 
validated assay  based on liquid chromatography -
tandem mass spectrometry (LC- MS/MS). 
Rationale for change As none of the measured metabolites is active, 
metabolite assessment is not necessary  and does 
not add any important additional information to 
the study . Following validation of a BIBF 1120 
only bioanal ytical assay , it is now possible to 
measure just one anal yte. Only  pre-dose plasma 
concentration of nintedanib will be measured.
Section to be changed Section 5.5.1 Blood, serum and RNA samples for 
pre-specified biomarker anal yses.
Description of change Overall, approximately  72.5 mL  blood will be 
taken for exploratory  biomarker assessment and 
banking during the course of the trial.
Was changed to:
Overall, approximately  114 mL blood will be 
taken for exploratory  biomarker assessment and 
banking during the course of the trial.
Rationale for change Correction of blood volume to be collected for the 
analysis of biomarkers.
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 92of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Number of global amendment 2
Date of CTP revision 18Aug 2016
EudraCT number 2015-002619-14
BI Trial number 1199.36
BI Investigational Product(s) nintedanib
Title of protocol A 24 -week, double -blind, randomized, parallel -
group stud y evaluating the efficacy and safet y of 
oral nintedanib co -administered with oral 
sildenafil, compared to treatment with nintedanib 
alone, in patients with idiopathic pulmonary  
fibrosis (I PF) and ad vanced lung function 
impairment
To be implemented only after 
approval of the IRB / IEC / 
Competent AuthoritiesYes
To be implemented 
immediately in order to 
eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
change with request for 
approvalNo
Can be implemented without 
IRB / IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects onlyNo
Section to be changed Title
Description of change A 24 -week, double -blind, randomized, parallel -
group stud y evaluating the efficacy and safet y of 
oral nintedanib co-administered with oral 
sildenafil, compared to treatment with nintedanib 
alone, in patients with idiopathic pulmonary  
fibrosis (I PF) and advanced lung function 
impairment
Was changed to :
INSTAGETM: A 24 -week, double -blind, 
randomized, parallel- group study  evaluating the 
efficacy  and safet y of oral nintedanib co-
administered with oral sildenafil, compared to 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 93of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
treatment with nintedanib alone, in patients with 
idiopathic pulmonary  fibrosis (I PF) and adva nced 
lung function impairment
Rationale for change A trade name is now assigned for this study .
Section to be changed ABB REVIAT IONS
Description of change Was added :
FEV1 Forced Expiratory  Volume in 1 second
MACE Major Adverse Cardiovascular E vents
Rationale for change First definition was missing, second one was 
added.
Section to be changed Section 1.2.1 Nintedanib
Description of change Potential risks of nintedanib treatment also include 
arterial h ypertension, gastrointestinal perforations, 
thromboembolism and bleeding. 
Was changed to :
Risks of nintedanib treatment also include arterial 
hypertension, gastrointestinal perforations, 
thromboembolism , pancreatitis, thrombocytopenia
and bleeding. 
Rationale for change Addition of pancreatits and thrombocytopenia as 
risks of treatment with nintedanib in line with the 
new information provided in the I nvestigators 
Brochure (version 11, dated 21 Jul 2016).
Section to be changed Section 2.3 Benefit – Risk assessment
Description of change Potential risks of nintedanib treatment also include 
arterial h ypertension, gastrointestinal perforations, 
thromboembolism and bleeding. Therefore, 
patients requiring full dose concomitant 
anticoagulation, fibrinolysis or high -dose 
antiplatelet therap y will be excluded from this trial.
Was changed to :
Risks of nintedanib treatment also include arterial 
hypertension, gastrointestinal perforations, 
thromboembolism , pancreatitis, thrombocytopenia
and bleeding. Therefore, patients requiring full 
dose concomitant anticoagulation, fibrinol ysis or 
high-dose antiplatelet therapy  will be excluded 
from this trial.
Rationale for change Addition of pancreatitis and thrombocy topenia as 
risks of treatment with nintedanib in line with the 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 94of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
new information provided in the I nvestigators 
Brochure (version 11, dated 21 Jul 2016).
Section to be changed Section 3.1.1 Administrative structure of the trial
Description of change All death cases will be assessed (to evaluate the 
primary  cause of death) ,as well as all acute IPF 
exacerbations (based on written clinical reports, for 
diagnostic confirmation) by  an indep endent 
Adjudication Committee (AC) , in a blinded 
manner before data base lock. The tasks and 
responsibilities of the DMC and the AC will be 
specified in a charter. 
Was changed to :
All death cases will be assessed (to evaluate the 
primary  cause of death), as well as all adverse 
events categorized as major adverse cardiovascular 
events (MACE) and all acute I PF exacerbations 
(based on w ritten clinical reports, for diagnostic 
confirmation) b y an indep endent Adjudication 
Committee (AC) , in a blinded manner before data 
base lock. The tasks and responsibilities of the 
DMC and the AC will be specified in a charter. 
Rationale for change MACE events will also be assessed b y the 
Adjudication Committee
Section to be changed Section 3.3.2 I nclusion criteria 
Section 3.3.3 Exclusion criteria
Description of change 3.3.2 I nclusion criteria
5.DLCO (corrected for Hb) ≤ 35% predicted of 
normal at visit 1
Was changed to :
5.DLCO (corrected for Hb) ≤ 35% predicted of 
normal at visit 11
3.3.3 Exclusion criteria
4. Relevant airway s obstruction (i.e. pre -
bronchodilator FEV1/FVC <0.7 at visit 1);
Was changed to :
4. 
Relevant airway s obstruction (i.e. pre -
bronchodilator FEV1/FVC <0.7 at visit 1)1;
3.3.3 Exclusion criteria
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 95of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
9. Creatinine clearance < 30 mL /min calculated by  
Cockcroft –Gault formula (appendix 10.2) at visit 
1;
Was changed to :
9. Creatinine clearance < 30 mL /min calculated by  
Cockcroft –Gault formula (appendix 10.2) at visit 
11;
3.3.3 Exclusion criteria
15. Uncontrolled s ystemic hy pertension (SBP > 
180 mmHg ;DBP > 100 mmHg) at visit 1
Was changed to :
15. 
Uncontrolled s ystemic hypertension (SBP > 
180 mmHg orDBP > 100 mmHg) at visit 11
3.3.3 Exclusion criteria
23.Treatment for pulmonary  hypertension with 
prostaglandins (e.g., epoprostenol, treprostinil), 
endothelin -1 antagonists (e.g., bosentan, 
sitaxsentan, ambrisentan), phosphodiesterase 
inhibitors (e.g., sildenafil, tadalafil, vardenafil) or a 
stimulator of guan ylatcyclase (e.g., riociguat) 
within 4 weeks of visit 2;
Was changed to :
23.Treatment with prostaglandins (e.g., 
epoprostenol, treprostinil), endothelin -1 
antagonists (e.g., bosentan, sitaxsentan, 
ambrisentan), phosphodiesterase inhibitors (e.g., 
sildenafil, tadalafil, vardenafil) or a stimulator of 
guan ylatcyclase (e.g., riociguat) within 4 weeks of 
visit 2;
1Laboratory  parameters may be re -tested within the 
permitted timeframe, if found abnormal at Visit 1 
and thought to be a measurement error or was the 
result of a temporary  and reversible medical 
condition.
Was changed to :
1Laboratory  parameters, blood pressure and lung 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 96of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
function tests may  be re -tested with in the permitted 
timeframe, if found abnormal at Visit 1 and 
thought to be a measurement error or was the result 
of a temporary  and reversible medical condition.
Rationale for change To allow retest within the screening period of 
examinations required to assess inclusion criterion
#5 and exclusion criteria 4, 9 and 15. Clarification 
of exclusion criterion #15 and #23.
Section to be changed Section 4.2.2 Restrictions
Table 4.2.2.1:1
Description of change Prior 
to 
rando
misatio
nDuring 
treatm
ent 
periodAfter 
Visit 7 
(Follow
-up 
Period)After 
early 
EOT9
Treatment for 
PAH with 
prostaglandins
3, endothelin -1 
antagonists4or 
phosphodieste
rase 
inhibitors5or a 
stimulator of 
guanylatcyclas
e 6Not 
permitt
ed in 
the 4 
weeks 
prior to 
visit 2 1Not 
permitt
edNot 
permitte
dNot 
permit
ted
Was changed to :
Prior 
to 
rando
misati
onDuring 
treatm
ent 
periodAfter 
Visit 7 
(Follo
w-up 
Period
)After 
early 
EOT9
Prostaglandins
3, endothelin -1 
antagonists4or 
phosphodiester
ase inhibitors5
or a stimulator 
of 
guanylatcyclas
e 6Not 
permitt
ed in 
the 4 
weeks 
prior to 
visit 2 1Not 
permitt
edNot 
permitt
edNot 
permitt
ed
Rationale for change Clarification of restricted concomitant therap y
Section to be changed Section 5.2.2 Forced Vital Capacit y, Carbon 
Monoxide Diffusion C apacity , Alveolar Volume, 
Oxygen Saturation and Arterialised Blood Gases
Description of change Oxygen saturation (S pO2) will be measured at rest 
by standard pulse oximetry  (unaffected skin of 
earlobe or forehead ). Arterialised blood gases 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 97of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
(PaO 2and PaCO 2) will be measured in selected 
sites experienced in earlobe capillary  blood gas 
sampling. V alueswill be entered in theeCRF.
Was changed to:
Oxygen saturation (S pO2) will be measured at rest 
by standard pulse oximetry  (unaffected skin of 
earlobe or fingertip) . Arterialised blood gases 
(PaO 2and PaCO 2) will be measured in selected 
sites experienced in earlobe capillary  blood gas 
sampling. V alueswill be entered in theeCRF.
Rationale for change Correction of the siteformeasurement of ox ygen 
saturation.
Section to be changed Section 5.2.3 Acute IPF exacerbations
Description of change Acute IPF exacerbations are defined as otherwise 
unexplained clinical features within one
month, including all of the following:
Unexplained worsening or development of 
dyspnoea within 30 day s;
New diffuse pulmonary  infiltrates on chest X -
ray, and/or new HRCT parench ymal
abnormalities with n o pneumothorax or pleural 
effusion (new ground -glass opacities) since the 
last visit;
Exclusion of infection as per routine clinical 
practice and microbiological studies;
Exclusion of alternative causes as per routine 
clinical practice, including left hear t failure, 
pulmonary  embolism or any  identifiable cause 
of acute lung injury .
Was changed to :
Acute IPF exacerbation is defined as an acute, 
clinically  significant, respiratory  deterioration 
characterized b y evidence of new widespread 
alveolar abnormality  [P16-06899]. 
Extra -parench ymal causes (e.g. pneumothorax, 
pleural effusion, pulmonary  embolism) should be 
excluded and the following 3 diagnostic criteria 
need to be met:
Acute worsening or development of dy spnea 
typicall y of less than one mon th duration;
Computed tomograph y with new bilateral 
ground -glass opacit y and/or consolidation 
superimposed on a background pattern 
Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 98of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
consistent with usual interstitial pneumonia 
pattern;
Deterioration not fully  explained by  cardiac 
failure or fluid overload.
Events that are clinically  considered to meet the 
definition of acute exacerbation of I PF but fail to 
meet the three diagnostic criteria due to missing 
computed tomograph y data will be termed 
“suspected acute exacerbations” by the 
Adjudication Committee.
Rationale for change Update of the definition of acute IPF exacerbation 
in line with new definition recentl y published b y 
an international working group (Collard et. al. 
2016)
Section to be changed Section 5.5.2 Biobanking (optional)
Description of change Was added :
If not authorized by  a local I RB / IEC / Competent 
Authority , biobanking will not be performed for 
patients of the respective site / country  (as 
applicable).
Rationale for change Clarification that biobanking is an optional 
procedure and requires local approval.
Section to be changed Section 6.2.1 Screening and run -in period(s)
Description of change Patients who have a laboratory  test value that is 
outside the range specified by  the exclusion criteria 
may have the test repeated once to determine 
eligibility ; however, the result must be available 
prior to visit 2.
Was changed to :
Patients who have a laboratory  test, blood pressure 
or lung function test value outside the range 
specified b y the exclusion criteria and thought to 
bea measurement error or the result of a temporary 
and reversible medical condition may have the test 
repeated once to determine eligibility ; however, 
the result must be available prior to v isit 2 .
Rationale for change To allow retest within the screening period of 
examinations required to assess inclusion criterion 
#5 and exclusion criteria 4, 9 and 15.
Section to be changed
Description of change

Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 99of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
Rationale for change
Section to be changed Section 9.1
Description of change Was added :
P16-06899 Collard HR, Ry erson CJ, Corte TJ, 
Jenkins G, Kondoh Y, L ederer DJ, et al
Acute exacerbation of idiopathic pulmonary  
fibrosis: an international working group report. Am 
J Respir Crit Care Med, (2016)
Rationale for change Reference added
Section to be changed Section 10.2
Description of change In the presence of a surgical lung biops y, the 
histology  should be reviewed based on the
ATS/ERS/JRS/AL AT guidelines [ P11-07084]. An 
HRCT "possible I PF" coupled with a
surgical biopsy  of “definite UI P” or "probable 

Boehringer Ingelheim 18 Aug2016
BI Trial No.: 1199.36
c03484701-03 Trial Protocol Page 100of 100
Proprietary confidential information © 2016 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
UIP", upon multidisciplinary  team discussion,
could qualify  for inclusion as “consistent with 
IPF”.
Was changed to :
In the presence of a surgical lung biops y, the 
histology  should be reviewed based on the 
ATS/ERS/JRS/AL AT guidelines [ P11-07084]. An 
HRCT pattern "possible UIP" coupled with a 
surgical biopsy  pattern “definite UIP” or "probable 
UIP", upon multidisciplinary  team discussion, 
could qualify  for inclusion as “consistent with a 
diagnosis of IPF”.
Rationale for change Correction/r ewording according to the guidelines.
   
 
APPROVAL / SIGNATURE PAGE 
 Document Number:  Technical Version Number:  
Document Name:  
  
                                                                                                                  
Title:  
 
 
 
                                                                                                                    
Signatures (obtained electronically) 
 
Meaning of Signature  Signed by Date Signed 
 
   
  
 
   
  
 
   
  
 
   
  
 
   
  
 
   
  
 
   
   
 
  
  
 c03484701 3.0
clinical-trial-protocol-version-03
INSTAGE: A 24-week, double-blind, randomized, parallel-group study evaluating
the efficacy and safety of oral nintedanib co-administered with oral sildenafil,compared to treatment with nintedanib alone, in patients with idiopathic pulmonaryfibrosis (IPF) and advanced lung function impairment
Author-Trial Clinical Monitor 18 Aug 2016 13:15 CEST
Approval-Team Member Medical
Affairs18 Aug 2016 13:28 CEST
Approval-Project Statistician 18 Aug 2016 13:51 CEST
Approval-Team Member MedicalAffairs18 Aug 2016 14:12 CEST
Approval-Therapeutic Area 18 Aug 2016 14:21 CEST
Author-Trial ClinicalPharmacokineticist22 Aug 2016 08:21 CEST
Verification-Paper SignatureCompletion22 Aug 2016 21:01 CEST

Boehringer Ingelheim Page  2 of 2
Document Number:  Technical Version Number :  
 
 (Continued) Signatures (obtained electronically) 
 
Meaning of Signature  Signed by Date Signed 
 
   
  
 
 
  
  
  
 
  
 
    
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 c03484701 3.0